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 CHAPTER 1 – A MUTATION (L69P) IN THE PAS DOMAIN OF THE HERG 
CHANNEL IMPAIRS CHANNEL FUNCTION AND LEADS TO TRAFFICKING 
DEFECTS 
 
 Abstract 
The congenital long QT syndrome (LQTS) is a cardiac disorder characterized by a prolonged 
QT interval on the electrocardiogram and an increased susceptibility to ventricular arrhythmias 
and sudden cardiac death. Mutations in the KCNH2 gene (also known as the human ether-a-
go-go-related gene or hERG) can cause a reduction in the potassium current IKr, which is 
responsible for cardiac repolarization.  
In a patient with a clinically diagnosed LQTS we identified the mutation L69P in the PAS (Per-
Arnt-Sim) domain of the hERG channel. Functional expression of mutant channels in HEK293 
cells unveiled a reduced hERG channel function and an impaired trafficking to the plasma 
membrane compared to the wild type (WT) channel. Lowering the incubation temperature of 
hERG-L69P mutant expressing HEK293 cells to 27°C, a measure which should promote 
folding of the channel, did not appreciably improve channel trafficking. Three additional hERG 
channel variants with mutations at the same position exhibited larger currents than the hERG-
L69P mutant but with different inactivation/deactivation kinetics compared to the WT channel. 
In conclusion, the results imply that the loss of the conserved amino acid leucine at position 
69 in the PAS domain of the hERG protein has a negative effect on the functional properties 
of the channel as well as on its trafficking to the plasma membrane. Therefore, the functional 
and trafficking defects of this mutant support the clinical diagnosis of a LQTS. 
 
 Introduction 
The KCNH2 or hERG (human ether-a-go-go-related gene) gene encodes the α-subunit of a 
voltage-gated potassium channel Kv11.1, which conducts the rapidly activating delayed 
rectifier potassium current (IKr). With these properties it is an important component in the 
repolarization of the cardiac action potential [1,2]. The hERG channel is a multi-domain protein, 
which contains an amino-terminal Per-Arnt-Sim (PAS) domain [3], the voltage sensor (S1-4) 
and pore domains (S5-6) [4] and a carboxy terminus with the cyclic-nucleotide-binding 
homology domain (CNBD) [5]; the part of the channel between S1 and S6 is located in the 
membrane (Fig. 1). Loss of hERG channel function due to inherited mutations is a frequent 
cause of the long QT syndrome type 2 (congenital LQTS), which is characterized by a delayed 
ventricular repolarization (prolonged QT interval on the ECG) and an increased risk for fatal 
arrhythmias and sudden cardiac death (SCD) [6]. In addition, loss of hERG channel 
functionality can be caused by off-target drug effects (acquired LQTS) [7].  
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Fig. 1: Schematic linear topology of the hERG channel protein. 
The hERG protein consists of following domains: The N-terminal eag/PAS (Per-Arnt-Sim) domain (amino acids 1-
135), the proximal domain (residues 136-397), the transmembrane domain with six transmembrane helices S1-6 
(amino acids 398-667) and the carboxy terminus with the CNB domain (residues 668-867) (Modified from de la 
Pena et al. [8]). 
 
Over 300 suspected LQTS-causing missense mutations have by now been identified, but only 
half of them have been studied in heterologous expression systems [9,10]. Most of these 
missense mutations are leading to a reduction of the repolarizing outward potassium current 
(IKr) and cause a prolonged repolarization of the cardiac action potential. The dominant 
molecular mechanisms by which KCNH2 mutations cause a loss of hERG channel function 
are a disruption of channel gating and reduction of intracellular transport or trafficking to the 
plasma membrane [11]. The latter has been suggested early on as the predominant cause, 
but only recently a comprehensive study [10] could show that 88% of KCNH2 missense 
mutations in the PAS domain, CNB domain and pore domain produce trafficking deficient 
hERG channels. Additionally, this study showed that 70% of pore domain mutations produce 
a dominant negative effect, whereas PAS and CNB domain mutations did not [10]. 
In the present work, we identified a missense mutation in the KCNH2 gene in a case of LQTS. 
The mutation is located in the N-terminal PAS domain of the hERG channel and leads to a 
non-conservative amino acid substitution L69P. To test the impact of the natural L69P mutation 
and three experimentally constructed variants at this position on channel kinetics, we 
performed patch-clamp measurements HEK293 cells. Furthermore, we examined the 
trafficking of the hERG-L69P channel by imaging using intact HEK293 cells as well as isolated 
membrane patches. 
 
 Material and Methods 
1.3.1. Genetic analysis 
Genomic DNA was extracted from blood samples using standard phenol chloroform 
procedures. Polymerase chain reaction (PCR) was used to amplify 15 exons of KCNH2 with 
published [12] and own primers (see Appendix 2.7.1.). Direct sequencing of the amplicons was 
performed in the presence of fluorescence–labeled dideoxynucleotides (BigDye® Terminator 
Cycle Sequencing Kit, Life Technologies, Germany) and primers in both sense and antisense 
direction. Sequencing products were examined with a 3130xl Genetic Analyzer (Applied 
Biosystems, Germany). Sequence Data were analyzed with SeqScape v2.5 (Applied 
Biosystems, Germany) and compared to the NCBI (National Center of Biotechnology) 
reference sequence NG_008916. 
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1.3.2. Cloning of the KCNH2 mutations 
QuickChange®II XL Site-Directed Mutagenesis Kit (Stratagene, Agilent Technologies) was 
used to introduce the KCNH2-L69P, KCNH2-L69A, KCNH2-L69D and KCNH2-L69G   
mutations into the pEGFP-N2 vector with hERG (KCNH2). All constructs were verified by 
sequencing (Eurofins, Ebersberg, Germany). 
 
1.3.3. Expression of hERG channels in HEK293 cells 
Human Embryonic Kidney (HEK293) cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM/Ham’s F-12, Biochrom AG, Berlin, Germany) supplemented with 2 mM glutamine, 
10% fetal calf serum (Sigma-Aldrich GmbH, Taufkirchen, Germany) and 1% 
penicillin/streptomycine solution (Sigma-Aldrich GmbH, Taufkirchen, Germany) under 5% CO2 
and at 37°C. For patch clamp measurements, the HEK293 cells were grown in 35 mm plates 
to a confluency of 60-70% and transiently transfected with 1 µg plasmid DNA using Gene Juice 
(Novagen, Merck, Darmstadt) or Turbofect (Thermo Fischer Scientifics, Waltham, MA, USA) 
according to the manufacturer’s protocol. One day after transfection the cells were isolated 
and transferred to new 35 mm plates in different concentrations. For confocal laser scanning 
microscopy (CLSM) the HEK293 cells were grown and transfected as mentioned above but on 
25 mm round glass coverslips. 
 
1.3.4. Patch clamp measurements in HEK293 cells  
Patch clamp recordings were performed 48 h after transfection with an EPC-9 amplifier (HEKA, 
Lambrecht, Germany) in the whole cell configuration using borosilicate glass pipettes (Tube 
capillary, Melting point, 1,5-1,8 mm, Kimble Chase, Gerresheimer, Vineland, USA) with a tip 
resistance of 2-5 MΩ. The extracellular bath solution contained 140 mM NaCl, 5,6 mM KCl, 
1,2 mM MgCl2, 2,6 mM CaCl2 and 10 mM HEPES (pH 7,4, adjusted with NaOH). The internal 
pipette solution contained 140 mM KCl, 10 mM EGTA, 5 mM MgCl2, 2 mM CaCl2, 5 mM HEPES 
(pH 7,2, adjusted with KOH) and 5 mM ATP. All currents were recorded at room temperature. 
The voltage protocols are presented in the respective Figure legends. 
 
1.3.5. Plasma membrane preparation 
HEK293 cells were cultivated and transfected as described in section 2.3.3. Plasma membrane 
preparation was performed according to [13]. 24 h after transfection the cells were detached 
by swilling with phosphate buffered saline (PBS) and centrifuged for 4 minutes at 2.500 rpm 
(Biofuge pico, Heraeus, Hanau, Germany). The cell pellet was resuspended in 1 ml PBS. 300 
µl of the cell suspension was transferred on a poly-D-lysine (PDL) coated, 25 mm round glass 
coverslip that was placed in a 35 mm round culture dish. After filling with 2 ml PBS the cells 
were incubated for 15 minutes. During this incubation step the cells attached to the poly-D-
lysine surface of the pre-treated coverslip. The PBS solution was then replaced by 2 ml ice-
cold ddH2O and incubated for 5 minutes. The osmotic stress led the cells to burst open. By 
following washing steps with ddH2O cell debris and organelles were removed and only plasma 
membrane patches firmly attached to the coverslip remained. 
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1.3.6. Confocal Laser Scanning Microscopy (CLSM) 
Confocal images were obtained 24-48 h after transfection on a Leica TCS SP5 II Confocal 
System equipped with an argon laser. Enhanced green fluorescent protein (EGFP) was excited 
with 488 nm and the emission was detected through a band pass filter between 500 and 530 
nm. The fluorescent marker Cellmask™ DeepRed (Invitrogen GmbH, Karlsruhe, Germany) was 
used for staining the plasma membrane of isolated membrane patches. Cellmask™ DeepRed 
was excited with 633 nm and the emission was recorded at 655-700 nm. Image acquisition 
was made with the HCX PL APO CS 100x1.44 OIL UV objective. The images were analysed 
using the LAS AF software version 2.60 (Leica Microsystems CMS GmbH, Heidelberg, 
Germany) and further edited with the open source software ImageJ (http://rsb.info.nih.gov/ij). 
 
1.3.7. Data analysis and statistics 
Electrophysiological data acquisition and analysis was performed with Patchmaster and 
Fitmaster software (HEKA, Lambrecht, Germany). Graphics of the current recordings and the 
corresponding I-V relationships were created with Igor Pro 6.03 software (WaveMetrics, Lake 
Oswego, OR). Data are expressed as mean ± standard deviation (SD) of n experiments. An 
unpaired student-t-test was used to evaluate the significance of differences in the relative 
fluorescence intensity between hERG-WT and hERG-L69P cells. 
 
 Results  
1.4.1. KCNH2 mutation analysis 
Genetic analysis was performed in the work of Kiehne [14]. Direct sequencing of the exon 
spanning region of KCNH2 revealed a heterozygous mutation L69P (c.206T>C, rs199473665) 
in a 35-year-old women suffering from dizziness and tachycardia in resting periods after 
physical stress (Fig. 2). A cardiological examination revealed no morphological abnormalities 
but the electrocardiogram (ECG) showed supraventricular systoles and tachycardia. First a 
Brugada syndrome (BrS) was assumed but further investigations unveiled a prolonged QT 
interval.  
 
 
Fig. 2: Electropherogram showing the heterozygous nucleotide change. 
Sequencing of the coding region of KCNH2 revealed a heterozygous nucleotide change at position 206 from 
thymine to cytosine (CTG  CCG) leading to an amino acid substitution on position 69 in the resulting protein. 
Highlighted in orange is the KCNH2 reference sequence. L = Leucine, P = Proline. 
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The KCNH2 L69P mutation has been previously associated with the Long-QT Syndrome 
(LQTS) [9]; the mutation is located in the N-terminal PAS domain of the hERG protein (Fig. 3). 
As can be seen in Fig. 4 the amino acid position 69 is highly conserved among different 
species. The PAS domain in hERG channels is crucial for maintaining normal cardiac activity. 
Previous studies have shown that mutations, which disrupt the PAS domain structure, can 
cause functional or trafficking defects associated with the LQTS [15–17]. 
 
 
 
Fig. 3: Schematic topology of the hERG channel and PAS domain structure. 
(A) Schematic representation of a hERG channel α-subunit showing the relative positioning of channel regions 
and domains. Transmembrane helices are labelled S1 to S6. PAS = Per-Arnt-Sim domain, CNBh = Cyclic 
Nucleotide Binding homology domain (modified from Morais-Cabral et al. [18]). (B) PAS domain structure 
including the position of the mutated amino acid leucine shown in red (PDB code: 1BYW [19]). 
 
 
Q12809 HUMAN … QRPCTCDFLHGPRTQRRAA … 
I0FG57 MACAQUE … QRPCTCDFLHGPRTQRRAA … 
Q8WNY2 RABBIT … QRPCTCDFLHGPRTQRRAA … 
Q9TSZ3 DOG … QRPCTCDFLHGPRTQRRAA … 
O35219 MOUSE … QRPCTCDFLHGPRTQRRAA … 
O08962 RAT … QRPCTCDFLHGPRTQRRAA … 
 
Fig. 4: Alignment of a part of the N-terminal hERG amino acid sequence from different species. 
Each amino acid sequence is preceded by its UniProt accession number. The mutated amino acid (L69P) is 
indicated in red. 
 
An additional evaluation of the mutation pathogenicity of KCNH2 L69P was performed using 
the sequence based programs PolyPhen-2 (Polymorphism Phenotyping v2), SIFT (Sorts 
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Intolerant From Tolerant), KvSNP (Single Nucleotide Polymorphism Prediction of Kv channels) 
and SNPs&Go. These tools are based on comparing sequence homologies and predict 
whether an amino acid substitution in a protein will have a phenotypic effect. The results are 
presented in table 1 and underline a potential detrimental effect of the L69P mutation. 
 
Table 1: Summary of pathogenicity prediction results. 
Protein CDS Prediction tool 
PolyPhen-2 SIFT KvSNP SNPs&Go 
p.L69P c.206T>C Probably damaging 
(1.000) 
Damaging 
 
Disease 
(0,959) 
Disease 
(8) 
Values in parentheses (0-1 for PolyPhen-2 and KvSNP and 1-10 for SNPs&Go) are a reliability index with larger 
values more reliable. CDS = coding sequences. 
 
1.4.2. Functional expression of hERG-WT and hERG mutants in HEK293 cells 
1.4.2.1. Voltage dependent hERG-WT and mutant hERG channel activation 
To investigate the voltage-dependent properties of the currents generated by the hERG-L69P 
mutant compared to the hERG-WT, the channels were transiently expressed in HEK293 cells 
and whole cell patch clamp recordings were performed (Bachelor thesis Johanna Schäfer, 
2014). The cells were therefore clamped from a holding potential of -80 mV to depolarizing 
voltages between -40 and +40 mV for 4 s to activate the hERG channel. For recording of the 
tail currents the cells were then clamped to -40 mV for 4 s (Fig. 5A).  
The endogenous currents of the non-transfected HEK293 cells were only elicited by 
depolarizing step more positive than -20 mV. The resulting small outward currents decreased 
after several milliseconds to a constant value (Fig. 5B). Figs. 5C and D show in comparison to 
this the voltage dependence of activation of hERG-WT and hERG-L69P, respectively. At 
depolarizing steps hERG-WT transfected cells exhibited large outward currents, which 
decreased at positive voltages due to the inherent inactivation of the hERG channel. During 
the repolarizing pulse (-40 mV) the channels recovered from inactivation and opened again. 
This transient opening generated the typical tail currents (Fig. 5C).  
The current response of the cell expressing the hERG-L69P mutant channel was clearly 
different from that recorded from the hERG-WT channel. The hERG-L69P transfected cells 
(Fig 5D) only generated small currents, which were much smaller than those recorded in the 
hERG-WT transfected cells (Fig. 5C). However, compared to the non-transfected HEK293 cell 
(Fig. 5A), the hERG-L69P cell exhibited a minimal tail current. This hERG typical tail current 
underscores that the mutant is active in the HEK293 cells.  
A plot of the steady state current as a function of the clamp voltage reports the corresponding 
current/voltage (I-V) relation of the measured cells (Fig. 5E). The I-V data show that the hERG-
WT channel was activated at voltages positive to -50 mV; the maximum outward current was 
present in response to voltage steps to +10 mV. At more positive voltages the I-V relation 
exhibited a negative slope conductance which has been attributed to the hERG typical voltage-
dependent channel inactivation [20,21]. The I-V relation of cells expressing the hERG-L69P 
mutant show an almost linear increasing curve with no apparent maximum. The current 
amplitude at the reference voltage of +10 mV was 565 pA for cells expressing the hERG-WT, 
126 pA for cells with the hERG-L69P mutant and 62 pA for non-transfected HEK293 cells. 
     Chapter 1 
7 
 
 
 
Fig. 5: Voltage dependent activation of hERG-WT channel and its hERG-L69P mutant. 
(A) Voltage clamp protocol. The cell was first clamped for 2 s to a holding potential (-80 mV); the hERG current 
was then activated by 4 s long depolarizing steps between -40 and +40 mV, and then clamped to -40 mV for 4s to 
elicit tail currents. Currents recorded from a non-transfected HEK293 cell (B), a cell transfected with hERG-WT 
(C) and a hERG-L69P expressing cell (D). (E) Corresponding steady state I-V relationship of cells in B-D; data 
were collected at the end of the depolarizing test pulses ( HEK293,  hERG-WT,  hERG-L69P). 
 
The tail current is a characteristic property of hERG channels and is induced at a clamp step 
from positive to negative voltages [22]. This transient current is a result of a conformational 
change of the hERG channel from an inactive state via an open state to the closed state. In a 
total of sixteen measurements, which were performed with hERG-L69P transfected cells, we 
observed two different populations with respect to the tail currents. Seven cells showed a 
minimal tail current (population 1) and nine cells displayed no measurable tail current 
(population 2) (Fig. 6A). The current recordings of the latter population rather resembled those 
from non-transfected HEK293 cells. The mean tail current in response to the voltage step from 
+40 mV to -40 mV was 546 ± 246 pA for hERG-WT, 40 ± 35 pA for hERG-L69P (population 
1), -23 ± 29 pA for hERG-L69P (population 2) and -16 ± 9 pA for non-transfected HEK293 
cells. 
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Fig. 6: Comparison of mean tail currents.  
Each plot represents the mean tail currents (±SD) determined from current recordings as in Fig. 5 at the voltage 
step from +40 mV to -40 mV. (A) hERG-WT n = 6, hERG-L69P (population 1) n = 7, hERG-L69P (population 2) n 
= 9, HEK293 n = 3. (B) Mean tail currents of hERG-L69P cells cultivated at 37°C or 27°C. 37°C n = 7, 27°C n = 4. 
  
Collectively the data show that the current responses of the hERG-L69P mutant were very 
small and the mutant channel did not show the voltage-dependent channel activation. 
Nonetheless some hERG-L69P expressing cells exhibited a minimal tail current (Fig. 6, 
population 1), therefore it can be concluded, that a few functional channels are presumably 
located in the plasma membrane. 
Previous studies have shown that PAS domain mutations result in folding and hence trafficking 
defects of the hERG channel [17,23]. Recently, Anderson et al. [10] demonstrated that the 
protein-trafficking for 80% of the mutations in the PAS domain could be rescued by lower 
incubation temperatures. To examine whether the trafficking of the hERG-L69P mutant 
channel is temperature-sensitive the HEK293 cells were incubated at 27°C. However, the 
current responses of these cells did not differ from cells incubated at 37°C (Bachelor thesis 
Johanna Schäfer, 2014, data not shown). Also, the mean tail current was not increased by 
lowering the incubation temperature (Fig. 6B). 
The replacement of the nonpolar amino acid leucine by the nonpolar, aliphatic amino acid 
proline seems to disturb the structural integrity of the PAS domain structure resulting in either 
a trafficking or a functional defect of the hERG channel, or both. Three additional point 
mutations at position 69 were constructed to determine the effect on hERG channel activation. 
The leucine was substituted with alanine (A), aspartic acid (D) or glycine (G). Alanine is also 
nonpolar but significantly smaller than leucine, whereas aspartic acid contains a negatively 
charged side chain. Glycine, without any side chain, is small and allows higher flexibility in 
contrast to the other amino acids. The mutants were expressed in HEK293 cells and analysed 
as described above. The patch clamp recordings revealed three different current responses: 
cells which were similar to non-transfected cells (“HEK293-like”), cells exhibiting a minimal tail 
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current and cells which generated a “hERG-like” current; in the latter case, the typical activation 
and deactivation properties of hERG channels have been recognized (Fig. 7). For further data 
analysis, only those cells were considered, which exhibited either the “hERG-like” phenotype 
or, in case of hERG-L69P, a minimal tail current. 
 
 
Fig. 7: Histogram showing the different current response phenotypes of the hERG mutants. 
The current recordings as in Fig. 5A with the four hERG mutants elicited three different current phenotypes. 
hERG-L69A: HEK293-like n = 4, minimal tail current n = 3, hERG-like n = 2, hERG-L69D: HEK293-like n = 2, 
minimal tail current n = 5, hERG-like n = 3, hERG-L69G: HEK293-like n = 8, minimal tail current n = 6, hERG-like 
n = 1, hERG-L69P: HEK293-like n = 9, minimal tail current n = 7. 
 
The current responses (Fig. 8A) and the corresponding I-V relation (Fig. 8B) show that the 
three additional hERG mutants (L69A, L69D and L69G) generated larger outward currents 
than the hERG-L69P mutant channel. Except for the hERG-L69G mutant, which exhibited 
even larger currents than the hERG-WT channel, the current amplitudes of the other two 
mutant channels were similar to the WT. The maximum outward current was at 0 mV: 404 pA 
for hERG-L69A and 594 pA for hERG-L69D. At +30 mV 1210 pA was measured for hERG-
L69G.  
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Fig. 8: Voltage dependent activation of hERG-L69P and three other mutant hERG channels. 
Currents were measured as in Fig. 5A. (A) Current responses of cells expressing the mutant hERG channels 
specified along the current traces. (B) Corresponding steady state I-V relation of hERG-WT and hERG mutants; 
currents were measured at the end of the depolarizing clamp steps (Data of hERG-WT and hERG-L69P are the 
same as in Fig. 5E). (C) Corresponding tail currents for hERG-WT and hERG mutants in response to different 
conditioning voltages.  hERG-WT,  hERG-L69P, ∆ hERG-L69A,  hERG-L69D,  hERG-L69G. 
 
The corresponding peak tail currents obtained for hERG-WT and the four hERG mutants at -
40 mV following a depolarization pulse to different voltages are depicted in Fig. 8C. The hERG 
channel mutants L69A, L69D and L69G generated larger tail currents than the hERG-L69P 
mutant but not as large as the hERG-WT channel. In the case of the hERG-WT channel and 
the mutant channels L69A and L69D the curves reach saturation at voltages ≥ 20 mV while 
the hERG mutant L69G did not reach saturation. 
In summary, the results demonstrate that all three mutated channel variants (L69A/-D/-G) are 
functional. They all exhibited currents, which are smaller than the WT channel but larger than 
the hERG-L69P mutant. Since some of the tested mutants generate, different from the hERG-
     Chapter 1 
11 
 
L69P mutant, a “hERG-like” current (Fig. 7), it can be assumed that the effect of these variants 
on channel function is not as dramatic as for L69P. 
 
1.4.2.2.  The fully activated I-V relation of hERG mutant channels compared to the WT    
channel                                   
The fully activated I-V relation for hERG-transfected cells expressing either mutant (L69P/-A/-
D/-G) or WT channels was obtained by applying the pulse protocol shown in Fig. 9A. The 
hERG current was activated and partially inactivated by a depolarizing step to 60 mV for 1 s, 
followed by repolarizing steps to different voltages. With repolarizing steps to more negative 
voltages, the hERG current recovered from inactivation and reached a peak value from which 
it underwent a voltage-dependent decrease (Fig. 9B). Fig. 9C shows the corresponding I-V 
relation of the peak current recorded during repolarization for hERG-WT and mutant channels. 
The maximum outward current for hERG-WT was obtained at -30 mV followed by a decrease 
at more positive voltages. In cells expressing the hERG-L69P mutant channel the current did 
not reach a maximum and the I-V relation had the same shape as that from non-transfected 
HEK293 cells. The hERG-L69A and hERG-L69D transfected cells exhibited a small reduction 
in absolute current amplitudes compared to the hERG-WT transfected cell, with a current 
maximum at -10 mV. The I-V relation obtained for the hERG-L69G mutant is clearly shifted to 
more positive voltages with a current maximum at 20 mV.  
This shift of the I-V curve of the fully activated channel is difficult to explain. It could mean that 
the mutation has an effect on the selectivity of the channel. This explanation is rather unlikely 
since the PAS domain is far away from the selectivity filter, which dictates the K+ selectivity of 
the channel. Another explanation may suggest that the mutation alters the kinetics of the 
channel in such a way that it is not fully activated by the voltage protocol. This interpretation 
seems more likely considering the fact that the currents, which were conducted by this mutant 
exhibited strong differences in the kinetics compared to the other mutants (see for example 
Fig. 11). 
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Fig. 9: The fully activated I-V relation of hERG-WT and hERG mutant currents. 
(A) Voltage clamp protocol. A cell was depolarized to 60 mV for 1 s to activate and partially inactivate the hERG 
current. This step was followed by repolarizing steps between -100 and 40 mV. (B) Typical current responses of a 
non-transfected HEK293 cell, a cell expressing either hERG-WT or the hERG mutants (L69P/-A/-D/-G). (C) 
Corresponding fully activated I-V plot of the peak currents during repolarization (measuring point indicated by ♦). 
 HEK293,  hERG-WT,  hERG-L69P, ∆ hERG-L69A,  hERG-L69D,  hERG-L69G. 
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1.4.2.3. Inactivation properties of mutant hERG channels (L69A/-D/-G) 
To determine the rates of inactivation of cells expressing WT and mutant hERG channels a 
three-step pulse protocol was used (Fig. 10A, see also [22]). The cells were depolarized to 60 
mV for 200 ms to ensure that all hERG channels were fully inactivated. By applying a short 
pulse (-100 mV for 2 ms) the channels recovered from inactivation without significant 
deactivation. To observe the inactivation of the hERG current a series of test pulses (between 
-20 and 60 mV) was applied. The rates of inactivation could only be determined for cells 
expressing the mutant hERG channels L69A, L69D and L69G, which exhibited the 
characteristic hERG current. In Fig. 10B exemplary current responses of hERG-WT and the 
three mutant hERG channels are shown. The rate of inactivation at different voltages was 
measured by fitting a single exponential function to the decay of the different current traces. 
The resulting time constants were plotted as a function of the membrane potential (Fig. 10C). 
The time constants of hERG inactivation at -20 mV are presented in Fig. 10D. Considering the 
individual measurements there is no difference in inactivation kinetics at -20 mV between 
hERG-WT and the mutant channels hERG-L69A and hERG-L69D in the range of experimental 
error. For the cell expressing the hERG-L69G mutant the exponential fitting of the current 
traces at -20 and 0 mV was not possible, because inactivation at these voltage steps was 
hardly visible. 
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Fig. 10: Rates of inactivation of WT and mutant hERG channels. 
(A) A triple pulse protocol was used to determine the rate of channel inactivation at different voltages. The hERG 
current was activated and inactivated by a 200 ms long depolarizing pulse to 60 mV. A short repolarizing pulse        
(-100 mV for 2 ms) was used to allow the channels to recover from inactivation without appreciable deactivation. 
The membrane was then stepped to test voltages ranging from -20 to 60 mV during which the channels re-
inactivated. (B) Current traces of hERG-WT and three hERG mutants (L69A/-D/-G) in response to the triple pulse 
protocol. (C) The corresponding time constants at the individual test voltages were determined by fitting the 
current traces with a single exponential function. The time constants (τ) are plotted as a function of the membrane 
potential (V). (D) Time constants of hERG inactivation at -20 mV:  hERG-WT (n = 5): 30.1 ± 20.7 ms, ∆ hERG-
L69A: 13.6 and 18.1 ms,  hERG-L69D: 11.8 and 13.8 ms,  hERG-L69G: not determined (n.d.). 
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1.4.2.4 Deactivation rates of mutant hERG channels (L69A/-D/-G) 
The deactivation rates of hERG-WT and hERG mutant (L69A/-D/-G) channels were measured 
using the voltage clamp protocol shown in Fig. 11A. The hERG channels were activated by 
applying a pulse of 60 mV followed by a series of test pulses ranging from -100 to -20 mV 
during which the cells elicited tail currents. The respective current traces of hERG-WT and 
mutant channels were biphasic (Fig. 11B). A scrutiny of the current trace at -100 mV shows a 
rapid increase in current in the first phase; this reflects the fast recovery of channels from 
inactivation. In the second phase the tail currents decayed due to channel deactivation. The 
rate of current deactivation was determined by fitting these tail currents with the sum of two 
exponential functions. The time constants of the fast and slow component of deactivation 
measured at -100 mV are shown in Fig. 11C. The time constants for the fast component of 
deactivation were similar for hERG-WT (1.5 ± 0.6 ms) and the hERG mutants L69A (1.6 and 
1.9 ms) and L69D (1.4 ± 0.2 ms). In case of the mutant channel hERG-L69G the fast 
component could not be identified. Considering the time constants for the slow deactivating 
component there was an apparent difference between hERG-WT and its mutant channels. The 
time constants were 73.4 ± 51.6 ms for hERG-WT, 8.9 and 9.5 ms for hERG-L69A, 11.6 ± 2.5 
ms for hERG-L69D and 31.7 ms for hERG-L69G (only one current recording). Due to the fact 
that sample size of hERG mutants was very small, a statistical analysis of the time constants 
for the slow deactivating component was not possible. Hence, evaluating more samples might 
confirm the apparent difference in deactivation kinetics between hERG WT and hERG mutant 
channels. 
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Fig. 11: Deactivation properties of hERG-WT and hERG-L69A/-D/-G. 
(A) The deactivation kinetics were determined using the following pulse protocol: After applying an activating 
pulse of 60 mV the tail currents were recorded at potentials ranging from -100 to -20 mV. The tail currents at -100 
mV were fitted with the sum of two-exponential functions. (B) Representative hERG current recordings of WT and 
mutant channels. WT current trace in inset shows the fitting with the sum of two exponential functions (red trace) 
to illustrate the calculation of the time constants for recovery from inactivation (τfast) and deactivation (τslow). (C) 
Time constants of the fast and slow components of deactivation. τfast:  WT (n = 5): 1.5 ± 0.6 ms, ∆ L69A (n = 2): 
1.6 and 1.9 ms,  L69D (n= 3): 1.4 ± 0.2 ms,  L69G not determined (n.d.); τslow:  WT (n = 5): 73.4 ± 51.6 ms, 
∆ L69A (n = 2): 8.9 and 9.5 ms,  L69D (n= 3): 11.6 ± 2.5 ms,  L69G (n = 1): 31.7 ms. 
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1.4.3. Confocal microscopy 
The results of the functional characterization of the hERG-L69P mutation, which is located in 
the N-terminal PAS domain of the protein, imply that the mutation has considerable impact on 
hERG current when expressed in HEK293 cells. Furthermore, also cells expressing three 
additional hERG channel variants (L69A/-D/-G) with mutations in the same site exhibited 
different kinetic properties (slow deactivation) compared to the hERG-WT channel.  
The reduction of the hERG current in case of the L69P mutation may be due to abnormal 
channel gating/kinetics or deficient protein trafficking to the cell membrane. Several studies 
have shown that mutations, which disrupt PAS domain structure, mainly cause trafficking 
defects [10,17,23–25]. To examine this possibility, the WT and mutant channels were tagged 
with EGFP and the cellular distribution of these constructs was monitored by CLSM. 
Representative images of HEK293 cells expressing the hERG-WT and mutant channels are 
depicted in Fig. 12. The cell expressing the hERG-WT channel exhibited a clear GFP 
fluorescence in the plasma membrane (Fig. 12A and B). Whereas in cells expressing the hERG 
mutants (Fig. 12A) the GFP fluorescence was stronger in intracellular compartments, like the 
perinuclear ring and the endoplasmatic reticulum, than in the plasma membrane (Fig. 12B).  
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Fig. 12: Cellular distribution of hERG-WT:EGFP and four EGFP-tagged hERG mutants. 
(A) CLSM images of HEK293 cells transfected with hERG-WT, hERG-L69P, hERG-L69A, hERG-L69D and 
hERG-L69G. Left are the EGFP fluorescent and right the transmitted light images. Scale bar 5 µm. (B) Zoomed 
part of the fluorescent images of HEK293 cells expressing hERG-WT and hERG-L69P, respectively. pr = 
perinuclear ring, pm = plasma membrane. Scale bar 5 µm.  
 
A differentiation between a GFP-labelled protein in the plasma membrane, in the cortical 
endoplasmatic reticulum or in vesicles close to the plasma membrane is very difficult with the 
resolution of a confocal microscope. Therefore isolated membrane patches as described by 
Guthmann [13] were examined by CLSM. With this method, it is possible to detect GFP-tagged 
proteins exclusively in the plasma membrane without the interference of intracellular 
compartments. Fig. 13 shows exemplary images of isolated plasma membrane patches of 
HEK293 cells expressing hERG-WT and hERG-L69P. The membrane patches were obtained 
from cells incubated at 37°C as well as 27°C to determine whether the trafficking of the hERG-
L69P mutant is temperature sensitive. The images show that all membrane patches, which 
were stained and identified with CellmaskTM DeepRed (panel b), contained GFP fluorescence 
(panel a). In all cases the co-localization of both fluorescent signals was evident in the top 
(panel c) as well as in the side view (panel d) of the membrane patches. The confocal images 
demonstrate that both channels, WT and mutant, were positively targeted to the plasma 
membrane. However, considering panel a in Fig. 13, the membrane patch with hERG-L69P at 
37°C (image 2a) exhibited a lower GFP fluorescence intensity. 
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Fig. 13: Isolated plasma membrane patches of hERG-WT:EGFP and hERG-L69P:EGFP 
HEK293 cells expressing either hERG-WT:EGFP or hERG-L69P:EGFP were incubated at 37°C or 27°C. Panel a 
and b show the fluorescence signal of GFP and CellmaskTM DeepRed in top view, respectively. Panel c shows an 
overlay of panel a and b. Panel d is a side view of panel c. Overlay images were created with ImageJ. Scale bar 5 
µm.  
 
To compare the relative GFP fluorescence of the membrane patches the green fluorescence 
in a defined area was measured using the software ImageJ. In a second step the relative value 
of the green fluorescence was divided by the corresponding value of the red channel; this 
normalized the data with respect to different laser intensities. The results of this analysis are 
shown in Fig. 14. A comparison of the relative fluorescence intensity of hERG-L69P at 37°C 
with that of hERG-WT at 37°C confirms the visual impression in that the mutant exhibits on 
average less GFP fluorescence in the plasma membrane than the WT. The difference is of 
moderate statistical significance (p = 0.046).  
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Fig. 14: Relative fluorescence intensities of isolated membrane patches. 
The images of membrane patches exhibiting EGFP fluorescence (Fig. 13, panel a) were analysed as described in 
the text. The relative fluorescence intensity (± SEM) was 0.24 ± 0.07 for hERG-WT 37°C (n= 10), 0.08 ± 0.02 for 
hERG-L69P 37°C (n = 8), 0.29 ± 0.13 for hERG-WT 27°C (n= 5) and 0.06 ± 0.01 for hERG-L69P 27°C (n= 7). 
 
The results of these experiments confirm that the hERG-L69P mutant with an altered PAS 
domain is positively targeted to the plasma membrane. But the data also stress that the 
mutation seems to interfere with the trafficking of the channel to the plasma membrane. In both 
growth conditions (37°C and 27°C) the relative density of the mutant channel in the plasma 
membrane is only about half of that seen for the hERG-WT channel. This 50% reduction in 
channel density can, however, not explain the electrical measurements, in which the current 
generated by the mutant is barely measurable. The results of these experiments stress that 
the L69P mutation affects not only the trafficking of the channel to the plasma membrane but 
also functional properties of the hERG channel (see 1.4.2.1., Fig. 6). 
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 Discussion 
Here we describe the functional characterization of the KCNH2 mutation L69P, which was 
identified in a female LQTS patient. The L69P mutation resides in the amino-terminal PAS 
domain of the hERG protein. The hERG PAS domain is a hot spot for missense mutations that 
result in a decreased trafficking of the channel [17,24] or in an accelerated rate of deactivation 
[15,26]. Both defects may lead to a prolongation of the QT interval resulting in long QT 
syndrome type 2 (LQTS2).  
The PAS domain (residues 1-135) contains the PAS core (residues 26-135), an N-terminal cap 
with an amphipathic helix (N-cap helix, residues 13-25) and a flexible N-terminal tail (residues 
1-12) [26–28]. In a recent study, it has been shown that the interaction between the N-cap 
amphipathic helix the core of the PAS domain plays a critical role in stabilizing the isolated 
PAS domain [29]. The authors therefore suggested that mutations in the PAS core, which 
disrupt this self-liganded structure, will lead to trafficking defects of the hERG channel. 
Furthermore, they demonstrated that channels lacking the PAS domain (∆2-135) traffic 
perfectly well. Thus, if the PAS domain is present, it must be intact and properly folded. In 
addition of being important for channel trafficking, the integrity of the PAS domain is essential 
for normal channel gating [30]. At least 61 PAS domain mutations have by now been linked to 
LQTS2 [10]. Only 13 (D16A, K28E, F29L, N33T, Y43C, G53R, R56Q, T65P, C66G, H70R, 
A78P, L86R and M124R) were so far characterized with electrophysiological recordings. The 
tested mutants revealed altered  deactivation kinetics as well as defects in the biogenesis of 
the channel [15,16,23,26,31–33]. 
In the present study, we performed patch-clamp measurements of mutant hERG channels in 
HEK293 cells. The hERG-L69P mutant channels only generated small currents compared to 
those recorded from hERG-WT channels. Nevertheless, this small current was still 
distinguishable from the endogenous currents in HEK293 cells. The current amplitudes of cells 
expressing the hERG mutants were slightly larger than those from non-transfected HEK293 
cells and most importantly some of the hERG-L69P transfected cells exhibited a minimal tail 
current, e.g. a current, which is typical for hERG channels. From these data, it can be 
concluded that some of the mutant hERG channels must have reached the plasma membrane 
and were able to conduct currents. The reduced current of the hERG-L69P mutant channel 
may be either explained by an abnormal channel gating or a deficient trafficking to the plasma 
membrane. It has been shown that defective protein trafficking is the dominant mechanism 
responsible for LQTS2 caused by KCNH2 missense mutations [10]. 
To visualise the cellular distribution of hERG-WT and hERG-L69P mutant channels in HEK293 
cells, EGFP-tagged channels were monitored by CLSM. While cells expressing the hERG-WT 
channel exhibited a clear GFP signal in the plasma membrane, the GFP fluorescence in hERG-
L69P expressing cells was stronger in intracellular compartments than in the plasma 
membrane. This impression was supported by the analysis of isolated plasma membrane 
patches. A comparative quantification of membrane patches showed that the relative 
fluorescence intensity of the hERG-L69P mutant was about 50% reduced compared to that of 
hERG-WT. The results of these experiments strongly suggest that the mutation causes a 
reduced trafficking of the channel protein to the plasma membrane. Previous studies have 
shown that such a deficient trafficking of hERG channels with missense mutations in the PAS 
core, which are located next to amino acid position 69 (T65P, C66G, F68L and H70R) can be 
improved by lowering the incubation temperature to 27°C [10,23]. A lower temperature 
presumably supports a correct folding of the protein. However, in the present study, the relative 
channel density at the plasma membrane as well as the current response of cells expressing 
the hERG-L69P mutant were not temperature-sensitive. These results indicate that the 
replacement of the conserved amino acid leucine with proline on position 69 seems deleterious 
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for the highly-ordered structure of the PAS domain. The consequence is an impaired trafficking 
and effects on the functional properties of the hERG channel. 
The crystal structure of the hERG PAS domain (PDB: 1BYW) [19] contains a five-stranded 
antiparallel β-sheet packed against a strand comprising a coil and a single turn of a 310 helix 
flanked by three α-helices. When mapped on this structure the L69P mutation is located at the 
C-terminal end of the single turn of this 310 helix (Fig. 15).  
 
 
Fig. 15: hERG PAS domain structure. 
Ribbon diagram with secondary structure elements. (A) Top view (from the membrane) and (B) side view with the 
310 helix nicely presented (arrow). The leucine 69 is visualised as red stick. Side chains of surrounding amino 
acids in a radius of 10 Å of leucine 69 are shown as green sticks.  
 
The side chain of leucine 69 intrudes into the hydrophobic core of the PAS domain (Fig. 15) 
and is additionally stabilized by hydrogen bonding to the backbone carbonyl of Y99 and C66. 
The presence of proline at the C-terminal cap of 310 helices is energetically disfavoured and 
might induce distortions [34]. Proline is a unique amino acid in that the side chain is cyclized 
back on to the backbone amide position. As a general consequence proline is unable to 
function as a hydrogen bond donor and this can function to introduce kinks into α-helices [35]. 
For this particular mutation, the kinking could affect the interaction to the β-sheet via the 
hydrogen bond to Y99; it might further abolish the 310 helix internal hydrogen bond to C66. 
Thus, it is very likely that the area around the L69P mutation is less structured than in the wild 
type protein. In contrast to other missense mutations, such as T65P, C66G, F68L and H70R, 
trafficking of the hERG-L69P mutant channel could not be restored by lowering the incubation 
temperature (27°C) indicating here a more serious structural effect.  
Three additional mutated channel variants (L69A, L69D and L69G) were constructed to further 
examine the effect of amino acid substitutions at this position on hERG channel trafficking and 
kinetics. CLSM images of HEK293 cells expressing the EGFP-tagged constructs indicated 
that, like in hERG-L69P expressing cells, all three channel variants exhibited a stronger GFP 
signal in intracellular compartments than in the plasma membrane. Considering the kinetic 
properties of these variants, HEK293 cells expressing hERG-L69A, -L69D and -L69G mutant 
channels generated larger currents than the hERG-L69P mutant channel; moreover, in 
contrast to hERG-L69P expressing cells, some of these mutated channel variants generated 
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a “hERG-like” current with the typical inactivation and deactivation properties of hERG 
channels. The results of these experiments suggest that the position L69 is sensitive to any 
kind of amino acid exchange. However, the substitution by a proline with the consequent kink 
formation of the amino acid chain seems to have the most deleterious effects.  
The PAS domain is crucial for regulation of deactivation in the gating of hERG channels [30]. 
Several studies showed that hERG channels with deletion of the N-terminal cap (∆2-25, [26]), 
the entire PAS domain (∆2-135, [19]) or most of the N-terminal region (∆2-354, [36]) result in 
5 to 10-fold faster deactivation rates compared to wild type channels. hERG channels with 
point mutations in the PAS domain also have accelerated deactivation kinetics [15,19,33]. In 
the present study, the hERG-L69A, -L69D and -L69G mutant channels revealed some 
accelerating effect on the slow deactivating component of the channel. However, due to the 
small sample size of additional hERG mutants, this trend could not be verified statistically. 
In summary, the characterization of the L69P mutant of hERG indicates that the replacement 
of the amino acid leucine in the highly-conserved region of the PAS domain has appreciable 
impact on trafficking and gating of the hERG channel. The fact that hERG channels with an 
alanine, aspartic acid or glycine at position 69 formed functional channels at the plasma 
membrane suggest that these substitutions did not have a gross effect on PAS domain 
structure like the substitution with proline. It is not known whether the functional or the 
trafficking defect of the hERG-L69P mutant cause the clinical phenotype, however, both 
defects support the diagnosis of a LQTS. 
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 Appendix 
1.7.1. KCNH2 Primer Sequences 
The coding region of the KCNH2 gene was amplified with published [12] and redesigned 
primers. The PCR conditions were partial modified by using dimethyl sulfoxide (5%/10% 
DMSO) or a GC PCR Kit (AmpliTaq Gold® 360 DNA Polymerase Kit, Applied Biosystems, 
Germany). 
Exon Forward Primer (5’ → 3’) Reverse Primer (5’ → 3’) 
Amplicon 
length 
(bp) 
Add on 
1 
 
GCG CCC GCA GTC CAG TCT 
 
 
GAC TCG CAC TTG CCG ACG CA 
 
335 
GC 
PCR 
2 
 
GGT CCC CGC TCA CGC GCA CTC TC 
 
 
TTG ACC CCG CCC CTG GTC GT 
 
231 
5% 
DMSO 
3 
 
GCC CAC TGA GTG GGT GCC AAG 
 
 
CCA CGA ACC CCT GAG CCT GCC 
 
165  
4 
 
CTC CGG GGC TGC TCG CGA T 
 
 
CAC CAG CGC ACG CCG CTC CT 
 
200 
10% 
DMSO 
 
GCC ATG GAC AAC CAC GTG GCA 
 
 
CCC AGA ATG CAG CAA GCC TG 
 
283 
10% 
DMSO 
5 
 
GGC CTG ACC ACG CTG CCT CT 
 
 
CCC TCT CCA AGC TCC TCC AA 
 
212 
 
6 
 
CAG AGA TGT CAT CGC TCC TG 
 
 
CAG GCG TAG CCA CAC TCG GTA G 
 
196 
 
 
TTC CTG CTG AAG GAG ACG GAA G 
 
 
TAC ACC ACC TGC CTC CTT GCT GA 
 
245 
 
7 
 
TGC CCC ATC AAC GGA ATG TGC 
 
 
CAG CCA GCC GAT GCG TGA GTC CA 
 
178 
 
 
TAG CCT GCA TCT GGT ACG C 
 
 
GCC CGC CCC TGG GCA CAC TCA 
 
236 
 
8 
 
TGG GGT CCC TGC AGA GGC TGA C 
 
 
CTT CCC AGC CTG CCA CCC ACT G 
 
200 
 
9 
 
GGC CTG GAG GTT GAG ATT TC 
 
 
GCG GTG CAT GTG TGG TCT TG 
 
188 
 
 
GCA CTG CAA ACC CTT CCG AG 
 
 
GGC ATT TCC AGT CCA GTG C 
 
165 
 
10 
 
TGA GCT CCC TGT CCT CTC CAT G 
 
 
CTC AGG GCA GCC AAC TCA CAT C 
 
194 
 
11 
 
GGT GGG GCA GGA GAG CAC TG 
 
 
TCC CCC GCC TCA CCC TTG TC 
 
93 
 
12 
 
CTC TGT TTC CCA CAG ACA CG 
 
 
CTG GGT GAG CGG GGT AGA CG 
 
360 
GC 
PCR 
13 
 
CCG CTC ACC CAG CTC TGC TCT C 
 
 
CAG GGC GTG CCC CCC CAC CCC 
 
227 
 
14 
 
ACT CCC GGT GGA GGC TGT CA 
 
 
GAA CAA GCG GGT CAC GGT AC 
 
178 
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15 
 
TCC TGT CCT CCC GTC CAT C 
 
 
TGT CCA CAC TGG GCA G 
 
155 
 
 
1.7.2. pEGFP-N2 Vector Information 
 
 
Fig. 16: Vector map of pEGFP-N2 
(www.bdbiosciences.com) 
 
1.7.3. Mutagenesis Primer Sequences 
                                                                                                                                                                       
KCNH2-L69P 
       
forward 
                                                                                                                                                       
5’-CCC TGC ACC TGC GAC TTC CCG CAC GGG CCG CGC ACG CAG C-3’ 
      
reverse 
                                                                                                                                                        
5’-GCT GCG TGC GCG GCC CGT GCG GGA AGT CGC AGG TGC AGG G-3’ 
 
                                                                                                                                                                       
KCNH2-L69A 
       
forward 
                                                                                                                                                       
5’-CCC TGC ACC TGC GAC TTC GCT CAC GGG CCG CGC ACG CAG-3’ 
      
reverse 
                                                                                                                                                        
5’-CTG CGT GCG CGG CCC GTG AGC GAA GTC GCA GGT GCA GGG-3’ 
 
                                                                                                                                                                       
KCNH2-L69D 
       
forward 
                                                                                                                                                       
5’-CCC TGC ACC TGC GAC TTC GAC CAC GGG CCG CGC ACG CAG-3’ 
      
reverse 
                                                                                                                                                        
5’-CTG CGT GCG CGG CCC GTG GTC GAA GTC GCA GGT GCA GGG-3’ 
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KCNH2-L69G 
       
forward 
                                                                                                                                                       
5’-CCC TGC ACC TGC GAC TTC GGA CAC GGG CCG CGC ACG CAG-3’ 
      
reverse 
                                                                                                                                                        
5’-CTG CGT GCG CGG CCC GTG TCC GAA GTC GCA GGT GCA GGG-3’ 
 
1.7.4. Amino acids 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
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 CHAPTER 2 – GENOTYPE-PHENOTYPE DILEMMA IN A CASE OF SUDDEN 
CARDIAC DEATH WITH THE E1053K MUTATION AND A DELETION IN THE 
SCN5A GENE 
 
 Abstract 
Mutations in the cardiac sodium channel gene SCN5A may result in various arrhythmia 
syndromes such as long QT syndrome type 3 (LQTS), Brugada syndrome (BrS), sick sinus 
syndrome (SSS), cardiac conduction diseases (CCD) and possibly dilated cardiomyopathy 
(DCM). In most of these inherited cardiac arrhythmia syndromes the phenotypical expression 
may range from asymptomatic phenotypes to sudden cardiac death (SCD).  
A 16-year-old female died during sleep. Autopsy did not reveal any explanation for her death 
and a genetic analysis was performed. A variant in the SCN5A gene (E1053K) that was 
previously described as disease causing was detected. Family members are carriers of the 
same E1053K variant, some even in a homozygous state, but surprisingly did not exhibit any 
pathological cardiac phenotype. Due to the lack of genotype-phenotype correlation further 
genetic studies were performed. A novel deletion in the promoter region of SCN5A was 
identified in the sudden death victim but was absent in other family members. 
These findings demonstrate the difficulties in interpreting the results of a family-based genetic 
screening and underline the phenotypic variability of SCN5A mutations. 
 
 Introduction 
Mutations in the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel 
Nav1.5, may cause either a gain or a loss of channel function. Gain-of-function mutations 
associated with an increase in the persistent late INa during the action potential plateau (Fig. 
17, phase 2), may lead to the long QT syndrome type 3 (LQTS) [1]. Loss-of-function mutations 
result in a decrease in peak INa (Fig. 17, phase 0) and are associated with a spectrum of 
arrhythmia phenotypes including Brugada syndrome (BrS) [2], sick sinus syndrome (SSS) [3], 
cardiac conduction diseases (CCD) [4] and possibly dilated cardiomyopathy (DCM) [5]. Most 
of the inherited cardiac arrhythmia syndromes show variable phenotypic severity ranging from 
absence of any symptoms to sudden cardiac death (SCD). Mixed phenotypes (overlap 
syndromes, e.g. presentation of ECG features of Brugada syndrome, conduction disorders and 
long QT syndrome type 3) have also been described [6,7].  
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Fig. 17: Major ion channel currents during the cardiac action potential. 
In response to a change in membrane potential a rapid influx of Na+ through voltage-gated channels occurs which 
generates the fast inward Na+ current (peak INa, phase 0, depolarization). Phase 1 is characterized by a transient 
outward K+ current (Ito) with fast activation and inactivation kinetics. The plateau phase (phase 2) is a result of 
inward currents as well as components of the outward rectifier current. The inward currents are due to a fraction 
of Na+ channels which were not inactivated at the end of phase 0 (late INa) and L-type Ca2+ channels which 
generate the Ca2+ current ICa. The components of the outward rectifier K+ currents are rapid IKr and slow IKs. 
During phase 3 (repolarization) outward rectifying K+ channels are dominant and Na+ and Ca2+ channels are 
inactivated. At the end of the repolarization phase the inward rectifier channel Kir generates IK1. At negative 
membrane potentials, this current is conducted more in the inward direction and sets the resting membrane 
potential close to the K+ equilibrium potential (-90 mV, phase 4). (Modified from Liu et al. [8]) 
 
The Brugada syndrome is an inherited autosomal-dominant arrhythmogenic disorder with 
characteristic electrocardiogram (ECG) abnormalities (Fig. 18). It is associated with an 
increased risk for SCD due to polymorphic ventricular tachycardia and/or ventricular fibrillation 
[9,10]. At present, seventeen genes have been putatively linked to BrS, but mutations in these 
genes are found only in about 25-35% of BrS cases [11]. Most rare variants are found in 
SCN5A and are present in 11-28% of the cases [12]. The clinical phenotype of a particular 
variant in the SCN5A gene may show a variable penetrance among individuals even within the 
same family. In some BrS-affected families, Probst et al. [13] found that SCN5A gene 
mutations are not solely causal for the manifestation of BrS and suggested that other factors 
beyond mutant sodium channels (e.g. genetic variation in other genes, alteration in 
transcription/translation, RNA processing and protein degradation) may contribute to different 
BrS phenotypes. More recent data present evidence that BrS might actually have an oligogenic 
basis [14]. 
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Fig. 18: Brugada syndrome ECG abnormalities. 
Typical BrS ECG abnormalities in the right precordial leads. (A) Type 1 ECG (diagnostic in BrS) is characterized 
by a J-wave amplitude or coved-type ST-segment elevation of ≥ 2 mm followed by a negative T-wave. (B) Type 2 
ECG is defined as a ≥2 mm J-wave elevation, ≥1 mm ST-segment elevation resulting in a saddle-back 
configuration, followed by a positive or biphasic T-wave. (C) Type 3 ECG shows a ST-segment elevation < 1 mm 
with either a coved or saddle-back appearance. Type 2 and 3 ECG patterns are not diagnostic rather than 
suspicious for BrS. (Modified from Mizusawa and Wilde [15]). 
 
The phenotypic variability associated with SCN5A mutations can also be partly explained by 
the co-inheritance of additional genetic variants in that gene. For example, the common 
SCN5A polymorphism H558R is known to be a disease modifying variant that can alter the 
effects of  gain- or loss-of-function mutations [16–18]. Hoshi et al. [19] showed that several 
apparently benign (or atypical) SCN5A mutations only lead to a BrS phenotype through a 
reduction in sodium current when expressed in a heterozygous state. Furthermore, SCN5A 
promotor variants, which cause variable transcription of the cardiac sodium channel gene, may 
contribute to the phenotypic variability of BrS. Bezzina et al. [20] studied the role of the genetic 
variation in the SCN5A promotor and identified six variants in close linkage disequilibrium, that 
could be associated with a reduced expression of the sodium channel as demonstrated in 
functional studies. This haplotype, found in people of Asian origin, could modulate the 
phenotypic expression of the Brugada syndrome. Additionally, multiple genetic variants in the 
SCN5A core promotor, which were found in BrS patients as well as in apparently healthy 
individuals, exhibit altered in vitro expression activity [21].  
Here we describe the difficulties in interpreting results of a postmortem genetic analysis in a 
case of sudden cardiac death. Besides a variant in the coding area of the SCN5A gene, a 
deletion in the promotor region in that gene was detected. Genetic screening of family 
members of the deceased revealed the presence of the variant, but not of the deletion; none 
of them showed clinically cardiac symptoms. 
 
 Material and Methods 
2.3.1. Clinical studies/Study subjects 
Following the sudden cardiac death (SCD) of a 16 years old female medico-legal autopsy was 
performed. Since no pathological findings were obtained postmortem, genetic screening was 
carried out in the context of the research project “molecular basis of diagnosis and etiology of 
genetic cardiovascular diseases as cause for sudden cardiac death” of the Institute of Forensic 
Medicine in Frankfurt. As this analysis revealed a potentially pathogenic variant, previously 
described as disease causing, the first-degree relatives were encouraged to seek genetic 
counseling. After obtaining informed consent of six family members, blood samples were 
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collected and analyzed. It was recommended for all family members to undergo cardiological 
assessment including resting and exercise ECG and Ajmaline testing.  
  
2.3.2. Genetic screening 
Genomic DNA was extracted from blood samples using standard phenol chloroform 
procedures. Polymerase chain reaction (PCR) was used to amplify 28 exons (excluding non-
coding exon 1) of SCN5A with published [22] and own primers (see Appendix 2.7.1.) Direct 
sequencing of the amplicons was performed in the presence of fluorescence–labeled 
dideoxynucleotides (BigDye® Terminator Cycle Sequencing Kit, Life Technologies, Germany) 
and primer in both sense and antisense direction. Sequencing products were examined with a 
3130xl Genetic Analyzer (Applied Biosystems, Germany). Data analysis was done with 
SeqScape v2.5 (Applied Biosystems, Germany) and the NCBI (National Center of 
Biotechnology) reference sequence NC_008934. In case of the homozygous carrier of the 
variant, the exon containing the sequence variant was amplified with a second set of primers 
to rule out the possibility of a primer binding site mutation in one allele. Variant filtering was 
performend with the ExAC database (Exome Aggregation Consortium) and a minor allele 
frequency (MAF) cut-off of <0.1% was used. 
 
2.3.3. Multiplex Ligation-dependent Probe Amplification (MLPA) 
MLPA is a semi-quantitative technique for detecting large deletions and duplications in a DNA 
sample. MLPA was performed on genomic DNA using the SALSA P108 SCN5A kit (MRC-
Holland, Amsterdam, the Netherlands) according to the manufacturer’s protocol. Three 
different control samples were included in each MLPA experiment. The SALSA P108 MLPA 
kit contains probes for each exon of the SCN5A gene (29 exons, including non-coding exon 1) 
and one probe upstream of exon 1. The amplification products were separated and identified 
by capillary electrophoresis using a 3130xl Genetic Analyzer (Applied Biosystems, Germany). 
Data analysis of the electropherograms was done with the Coffalyser.Net software 
(www.mlpa.com) performing two normalization steps of the MLPA peak pattern. Each probe 
peak of each sample was compared with the peaks of the reference probes (intrasample 
normalization). By comparing the relative probe peak of the sample to all control samples final 
probe ratios are calculated (intersample normalization). The resulting probe ratio for a normal 
DNA sample is ~1.0 (0.8-1.2), for a heterozygous deletion ~0.5 (0.4-0.65).  
 
2.3.4. Analyzing the SCN5A promotor region using Real-Time Quantitative PCR 
To confirm the deletion in the 5’ upstream region of the SCN5A gene real-time quantitative 
PCR (RT-qPCR) using DNA binding SYBR® GreenER™ (EXPRESS SYBR® GreenER™ qPCR 
SuperMixes and Two-Step qRT-PCR Kit, Invitrogen) and PCR Primers (see Appendix 2.7.2.) 
flanking the suspected boundaries of the deletion was performed. The method includes 
amplification of three segments in the 5’ upstream sequence of SCN5A  and two reference loci 
on chromosome 3 with normal copy number (GPR15 and ZNF80 [23]) for normalization. 
Amplification mixtures (20 µl) contained EXPRESS SYBR® GreenER™ master mix, 200 nM of 
each forward and reverse primer, 500 nM ROX reference dye and 1,25 ng template DNA. All 
reactions were performed in triplicates. The Applied Biosystems StepOnePlus™ Real-Time 
PCR System was used for the PCR reaction and the cycling conditions were as follows: 95°C 
for 2 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. Melting curve analysis was generated 
for every amplification product to ensure the specificity of the PCR reaction. Calculation of 
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copy numbers of the prospected segments was done with the Data Assist™ v3.01 Software 
(Applied Biosystems, Germany) using the comparative CT (∆∆CT) method [24]. Using GPR15 
(G Protein-coupled Receptor 15) and ZNF80 (Zinc Finger Protein 80) as reference genes with 
normal copy number, Hoebeek et al. [23] have shown that a copy number of ~1.0 (cut-off value 
≥0.8) is expected for a normal sample, while a heterozygous deletion would have a value of 
~0.5 (cut-off value ≤0.7). 
 
 Results 
2.4.1. Genetic analysis 
Sequencing of 28 exons (excluding non-coding exon 1) of the SCN5A gene revealed the 
heterozygous variant E1053K (c.3157G>A, rs137854617) in the deceased female (IV.3 Fig. 
19A and B). This rare variant has a minor allele frequency (MAF) of 0.014% in the European 
population (ExAC database) and has been previously associated with the Brugada [25,26] as 
well as with the Long-QT syndrome [27]. By cascade family screening the E1053K 
(heterozygous) variant was identified in the mother (III.4, age 47 years) of the deceased and 
in one cousin of the mother (III.2, age 57 years). Homozygous carriership of this variant was 
detected in one aunt (III.6, age 43 years, Fig. 19B) of the SCD victim. The other screened 
genes did not contain protein-altering variants at the variant-filtering cut-off of <0.1%. 
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Fig. 19: Identification of SCN5A variant E1053K in the family of the deceased.                                                                                                         
(A) Pedigree structure of the family of the deceased female. Square symbols indicate males, round symbols 
females and slashed symbols mark deceased individuals. The Roman numerals indicate the generation number, 
Arabic numerals each individual in a given generation. The arrow indicates the index patient. SCD = Sudden 
Cardiac Death, n.a. = not available. (B) Sequencing of the 28 exons of the SCN5A gene revealed a heterozygous 
nucleotide change in the index patient (left) and a homozygous nucleotide change in the aunt of the deceased 
(right). Highlighted in grey is the SCN5A reference sequence. E = glutamic acid, K = lysine. 
 
The SCN5A E1053K mutation is localized in the 9-amino acid ankyrin-G-binding motif 
(VPIAVA[EK]SD) of the DII-DIII loop of Nav1.5 [26] (Fig. 20). Ankyrin-G belongs to the family 
of the spectrin-binding proteins. It is required for the targeting of membrane proteins, especially 
ion channels like Nav channel isoforms, to excitable membranes [28]. The SCN5A variant 
E1053K inhibits the binding of the Nav1.5 channel to ankyrin-G and, therefore, the mutant 
channel is not efficiently targeted to cardiomyocyte membranes [26,29].  
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Fig. 20: Schematic topology of the α-subunit of the cardiac sodium channel Nav1.5.  
The four homologous domains DI-DIV are connected by extracellular and intracellular loops. The mutation 
E1053K is located in the intracellular linker loop 2 (modified from Abriel et al. [30]). 
 
2.4.2. Clinical examination 
A thorough clinical examination which included resting ECG (III.2, III.6 and IV.4), provocation 
test with the sodium channel blocker Ajmaline (III.2 and III.6), exercise ECG (III.2, III.6 and 
IV.4) and cardiac MRI (III.6) did not reveal any pathological phenotype neither in the 
heterozygous (III.2) nor in the homozygous carrier (III.6) of the E1053K variant (Ajmaline 
provocation test see Fig. 21). Regrettably, the mother (III.4) of the SCD victim refused any 
clinical examination and her parents had already died due to non-cardiac diseases. 
Considering the fact that the SCN5A variant E1053K did not lead to a pathological phenotype 
in the homozygous carrier, it is not very likely that this variant is the sole cause of death of the 
index patient. In addition, the minor allele frequency of 0.014% in the ExAC database is not 
compatible with being an independent pathogenic variant. 
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Fig. 21: 12-lead ECG during ajmaline challenge. 
12-lead ECG of the homozygous carrier (III.6) of the E1053K variant after intravenous injection of 60 
mg ajmaline. No abnormalities were detected. 
 
 
2.4.3. Detection of a deletion in the promotor region of SCN5A using MLPA 
By MLPA analysis a heterozygous deletion in the 5’ upstream region of SCN5A in the index 
patient was identified (Fig. 22A). This 5’ upstream sequence is a part of the SCN5A promotor 
region which has been characterized as an ~2.8 kb segment including ~2.1 kb of 5’ upstream 
sequence, the non-coding exon 1 and a part of the 16 kb intron 1 [31]. In several studies 
promotor variants functioning as positive and negative cis-acting elements have been 
identified, which are associated with various arrhythmia phenotypes [20,21,31,32]. A point 
mutation in the sequence detected by the MLPA probe SCN5A-up could be excluded, because 
no differences in the nucleotide sequence were detected by sequencing of this region (primer 
location see fig. 24). MLPA analysis of the first-degree relatives showed that none of the other 
family members carries the deletion in the 5’ upstream region of SCN5A. As an example, figure 
22B shows the MLPA result of the homozygous E1053K-carrier (III.6).  
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Fig. 22: MLPA analysis results. 
Each plot represents the relative peak ratios (±SD) for reference probes (white), SCN5A exon probes (grey) and 
one probe in the 5’ upstream region of SCN5A (dark). The solid line indicates the cut-off ratio of 0.7. (A) shows a 
heterozygous deletion of SCN5A-up in the index patient (IV.3). (B) and (C) shows the MLPA results for the 
homozygous carrier (III.6) and a control sample, respectively. 
 
Figure 23 summarizes the results of four MLPA runs for the probe SCN5A-up. The mean ratio 
(±SD) was 0.63±0.01 for the index patient, 0.92±0.04 for the homozygous E1053K-carrier 
(III.6) and 0.99±0.07 for control sample 1. Two-sample t-test (assuming unequal variation) 
indicate that the ratio was significantly different between the index patient and III.6 (p=0.0005) 
as well as between the index patient and control 1 (p=0.0015). 
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Fig. 23: Diagram showing the relative peak ratios for the MLPA probe SCN5A-up (n=4).  
Significance: ** p<0.01, *** p<0.001 
 
2.4.4. Real-Time Quantitative PCR 
To determine the extent of the deletion detected by MLPA, a real-time quantitative PCR (RT-
qPCR) was performed. The nomenclature proposed by Yang et al. [31] was adopted, where 
position +1 is the major transcription initiation site in SCN5A (Fig. 24). Three fragments (I: 
position -1845 to -1610, II: position -1964 to -1853, III: position -1606 to -1469) in the upstream 
region of SCN5A and two reference genes (GPR15 and ZNF80) for data normalization were 
amplified. The MLPA probe SCN5A-up binds at position -1740 to -1681 therefore fragment I is 
covering this region (Fig. 24). RT-qPCR was performed on genomic DNA of the index patient 
and of two healthy controls. 
 
 
Fig. 24: Locations of the primer used for sequencing and RT-qPCR. 
The MLPA probe sequence of SCN5A-up is highlighted in grey. The major transcription initiation site is indicated 
by ∆. The translation start site is located within exon 2 and is indicated by ▲.  
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The RT-qPCR revealed a deletion of fragment I (Fig. 25A) in the 5’ upstream region of the 
SCN5A gene from the index patient. The mean copy number (±SD) was 0.34 (±0.02) for 
fragment I, 1.02 (±0.09) for fragment II and 1.41 (±0.28) for fragment III, respectively. The copy 
numbers of fragment I were compared with the two-sample t-test (unequal variation) which 
demonstrates that the copy number is significantly different between the index patient and 
control I as well as control II (p<0.0001). In the two adjacent fragments, II and III, no deletion 
could be detected by RT-qPCR (Fig. 25B and C). 
 
 
Fig. 25: Haploid copy number values determined by RT-qPCR. 
Box-plot representation of copy numbers of fragment I-III obtained for the index patient and two normal controls. 
(A) The index patient harbours a deletion of fragment I in the upstream region of SCN5A (Significance: *** 
p<0.001). No deletion could be detected in the neighbouring fragments II (B) and III (C). 
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 Discussion 
In the present study, a heterozygous variant (E1053K) in the SCN5A gene of a 16-year-old 
female was identified who died suddenly during sleep. Medico-legal autopsy revealed no 
pathological findings. Genetic screening of the family members of the deceased revealed 
heterozygous carriership of this variant in her mother and in a cousin of second degree. Her 
aunt was a homozygous carrier of this variant. The SCN5A E1053K variant has been described 
previously in patients with BrS [25,26] as well as in a patient with LQTS [33]. Hence, a thorough 
cardiological examination of the relatives was performed, however, to our surprise these tests 
revealed no pathological phenotype neither in the heterozygous nor in the homozygous carrier 
of the variant, suggesting that the SCN5A E1053K variant alone is not disease causing and 
additional genetic factors may exist in the SCN5A gene of the index patient. Subsequent MLPA 
analysis and RT-qPCR identified a deletion in the SCN5A promotor region. Table 2 
summarizes the genetic and clinical findings for the affected family members. 
 
Table 2: Summary of the results of genetic and clinical examination. 
 
Genetic results Clinical diagnosis 
Index patient E1053K heterozygous 
Deletion (-1845 to-1610)  
SCD 
Mother E1053K heterozygous n.d. 
Aunt E1053K homozygous negative 
Second cousin E1053K heterozygous negative 
n.d. not determined 
 
Mohler et al. [26] demonstrated that the SCN5A E1053K variant, found in a patient with BrS, 
impairs binding of Nav1.5 channels to ankyrin-G. This leads to reduced membrane expression 
of the sodium channel in cardiomyocytes (albeit not in HEK293 cells). In a following study 
functional experiments had been performed using cardiomyocytes lacking ankyrin-G. The 
cardiomyocyte membranes exhibited a reduced total Na+ current, nevertheless, a residual Na+ 
current was detected [29]. The authors suggested that this current may reflect residual sodium 
channel activity or may represent the activity of other sodium channel isoforms. 
More recently Hoshi et al. [19] described apparently benign (also referred to as atypical) 
SCN5A BrS mutations, amongst which E1053K, that do not present the typical loss-of-function 
phenotype when expressed alone in heterologous expression systems such as HEK293 cells, 
but which lead to a decrease in sodium current when co-expressed with the wild-type sodium 
channel mimicking the heterozygous genotype in patients. They hypothesized that an impaired 
dimerization of two different Nav1.5 α-subunits may account for the results they obtained.  
Notwithstanding the observation made in vitro, E1053K genotype-phenotype relationships in 
the family we studied question the role of the E1053K variant in causing SCD, at least in 
isolation, since relatives carrying this variant heterozygously or homozygously do not exhibit 
clinical symptoms. The SCN5A H558R polymorphism, known to be a disease modifying variant 
in SCN5A mutation carriers [16–18], could be excluded in the index patient as well as in the 
other family members examined. Furthermore, considering that the SCN5A E1053K variant 
was previously identified in patients with clinical diagnosis of BrS [25,26,34] as well as in a 
patient with LQTS [33], representing disorders with distinct functional defects, and 
remembering the frequency in the ExAC database (0.014%) it can be concluded that this 
variant could not be the sole cause of death.   
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However, the deletion in the promotor region of the SCN5A gene in the index patient may be 
relevant. The deleted fragment is located in a region extending from position -1845 to -1610 
upstream of the major transcription initiation site (numbering based on SCN5A promotor 
RefSeq: AY313163 and according to [31]). Several studies have demonstrated the impact of 
promotor variants on the transcriptional activity of the SCN5A gene and it has been suggested 
that these variants may contribute to the variability of arrhythmia phenotypes [20,35–38]. Yang 
et al. [31] cloned and characterized the human SCN5A promotor. They identified and 
characterized various cis-acting DNA regulatory elements and described the functional effect 
of a single nucleotide polymorphism (SNP), which increased transcriptional activity in 
cardiomyocytes. Furthermore, Yang et al. [21] analysed subjects of various ethnical origins 
(including BrS patients and normal controls) and demonstrated that DNA variants are not 
uncommon in the SCN5A promotor region. Among the identified promotor variants, the SNP 
c.-225-1790 G>A significantly reduced the expression activity in cardiomyocytes and was 
suggested to modulate a putative transcription factor binding site. The described SNP position 
(c.-225-1790 G>A) is located within the deleted fragment (-1845 to -1610) that was identified 
in the SCN5A upstream region of the index patient. Therefore, this deletion may produce 
similar effects, although it is not known whether the deletion is present in the wild-type or in 
the mutant (E1053K) allele. In a recent study Yagihara et al. [38] identified variants in the 
promoter and in the transcription regulatory region of SCN5A which were associated with a 
variety of arrhythmia phenotypes. They hypothesized that variants in the SCN5A promoter may 
not be the sole cause of arrhythmias but they may modulate the susceptibility to arrhythmia 
syndromes. Taking this into account, the deletion detected in the index patient may affect the 
transcriptional activity of the SCN5A gene but this should be further elucidated.  
In conclusion, the genetic and clinical findings in the family suggest that E1053K-SCN5A is not 
an independent pathogenic variant. In functional studies sodium channels containing the 
E1053K variant exhibited a dysfunction that might contribute to a heightened risk for 
arrhythmias in the setting  of co-inheritance of additional genetic modifications such as genetic 
variations in the same or unrelated genes, alteration in transcription/translation, RNA 
processing or protein degradation [8,13] Interpretation of SCN5A mutations should therefore 
always be correlated carefully with regard to the clinical phenotype and rigorously evaluated 
considering additional genetic modifications. 
Genetic testing in sudden cardiac death cases is emerging as an important forensic tool to 
explain the cause of death. Based on the present and previous studies, genetic and 
cardiological assessment of the relatives of a SCD victim is recommended helping to 
understand genotype-phenotype relationships in this case using the example of a SCN5A 
variant. Elucidation of the cause of sudden cardiac death should always be embedded in a 
specialized multidisciplinary service with appropriately trained staff. 
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 Appendix 
2.7.1. SCN5A Primer Sequences 
References Primer Sequences [22] 
Exon Forward Primer (5’ → 3’) Reverse Primer (5’ → 3’) 
Amplicon 
length 
(bp) 
2 GGT CTG CCC ACC CTG CTC TCT CCT CTT CCC CCT CTG CTC CAT T 325 
3 AGT CCA AGG GCT CTG AGC CAA GGT ACT CAG CAG GTA TTA ACT GCA A 119 
4 GGT AGC ACT GGC CTG GCA GTG AT CCT GGA CAC AAG CCC CCT TC 90 
5 TCA CAC CAC GTA AGG AAC CTG ATG TGG ACT GCA GGG AGG AAG C 129 
6 CCT TTC CTC CTC TGA CTG TGT GT GGT ATT CTG GTG ACA GGC ACA TTC 92 
7 CCA CCT CTG GTT GCC TAC ACT G GTC TGC TGG TCT CAC AAA GTC TTC 231 
8 AGA GTG CCC CTC ACC AGC ATG GGA GAC TCC CCT GGC AGG ACA A 64 
9 GGG AGA CAA GTC CAG CCC AGC AA AGC CCA CAC TTG CTG TCC CTT G 142 
10 ACT TGG AAA TGC CAT AAC CCA GA CAC CTA TAG GCA CCT ACA GTC AG 198 
11 AAA CGT CCG TTC CTC CAC TCT AAC CAC AGC TGG GAT TAC CAT T 180 
12 
 
GGC CAG TGG CAC AAA AGA CAG GCT CCC TGG GCA CTG GTC CGG CGC A 181 
CAC CAC ACA TCA CTG CTG GTG C GGC ACT GGT GAT CAG TTT GGG AGA 200 
13 CCC TTT TCC CCA GGC TGA CGC AAA GTC TAA AGC AGG CCA AGA CAA ATG 133 
14 CTG GAA GGT ATT CCA GTT ACA TAT GA ACC CAT GAA GGC TGT GCC AGC TGC 239 
15 CTT TCC ATC CCA AAC AAT TCC T CCC CAC CAT CCC CCA TGC AGT 174 
16 
GAG CCA GAG CCC TTC ACA AGG TCC 
CCT 
CCC TTG GCC AAC TTA CCA CAA G 351 
17 
CTG GAT GGC TTG GCA TGG TGC AG GGG TGG CGG GGA GTA GGG GGT G 224 
GCC CAG GGC CAG CTG CCC AGC T 
CTG TAT ATG TAG GTG CCT TAT ACA 
TG 
228 
18 AGG GTC TGA AAC CCC CAG GGT CA CCC AGC TGG CTT CAG GGA CAA A 162 
19 GGC TCG AGG CCA AAG GCT GCT G CTA GGG CAG AGG GCT GCC CGG  225 
20 GGC ATT CAC AGG CCC TGA GGT GGG CTT TCC AGC TGG AGA CCT CCT TTC C 155 
21 TCC AGG CTT CAT GTC CAC CTT GTC T TCT CCC GCA CCG GCA ATG GGT 174 
22 GTC CCC AAC AGT GGG GAG CTG TTC CCG CCT CCC ACT CCC TGG TGG 123 
23 TTG AAA AGG GCA TGT GCT CTG GG CAC ATC ATG GGT GAT GGC CAT 282 
24 CTC AAG CGA GGT ACA GAA TTA AAT GA GGG CTT TCA GAT GCA GAC ACT GAT 54 
25 GCC TGT CTG ATC TCC CTG TGT GA CCT GGA GCC TGA GTG GCC CCT C 138 
26 CCA TGC TGG GGC CTC TGA GAA C GGC TCT GAT GGC TGG CCA TGT G 105 
27 CCC TGC TGA GCA CTT TCC ATT TG GCT TCT CCG TCC AGC TGA CTT GTA 271 
28 GCT GGC TGG AAG ACA GAG GTG C GGT GAT CTG GAA GAG GCA CAG C 280 
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AAG TGG GAG GCT GGC ATC GAC GTG CTC TCC TCC GTG GCC ACG C 263 
GAG CCC AGC CGT GGG CAT CCT GTC CCC ACT CAC CAT GGG CAG 268 
CCA ACC AGA TAA GCC TCA TCA ACA CCG CCT GCT GAC GGA AGA GGA 264 
TGC TGC AAC GCT CTT TGA AGC AT AAA GGC TGC TTT TCA GTG TGT CCT 300 
 
2.7.2. Real-Time PCR Primer Sequences 
Primer Sequences SCN5A upstream fragments and Reference Genes [23]  
Position Forward Primer (5’ → 3’) Reverse Primer (5’ → 3’) 
Amplicon 
length 
(bp) 
SCN5A upstream               
-1845 to -1610 
(fragment I) 
AGCTTCATTCTGAGGCCGAG GTACAGACGGATGGACCACA 237 
SCN5A upstream               
-1964 to -1853 
(fragment II) 
AGTGAAAACCCCACTTCTGCTA GCAAACTGACATTGGGTCAAGC 112 
SCN5A upstream              
-1606 to -1469 
(fragment III) 
CAGACACCCCACTCAACTCG GGGTGTGGGGCTTCGTTG 138 
GPR15   
Reference Gene 
[23] 
GGTCCCTGGTGGCCTTAATT TTGCTGGTAATGGGCACACA 101 
ZNF80    
Reference Gene 
[23] 
CTGTGACCTGCAGCTCATCCT TAAGTTCTCTGACGTTGACTGATGTG 120 
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 CHAPTER 3 – GENETIC MODIFIERS AS RISK FACTORS FOR LONG QT 
SYNDROME AND SUDDEN CARDIAC DEATH 
 
 Abstract 
Sequence variants in the ion channel genes KCNH2 and SCN5A may cause the cardiac 
disorder long QT syndrome (LQTS) which is characterized by a prolonged QT interval on the 
electrocardiogram (ECG) and cardiac events such as syncopes and sudden cardiac death 
(SCD). This disorder is further associated with an incomplete penetrance and a variable 
expressivity among KCNH2- or SCN5A-mutation carriers. In recent years, it became clear that 
common genetic variants, if associated with a mutation, may modulate disease severity in 
LQTS.  
In the SCN5A gene of a 17 years old female who died during sleep, the variants A572D and 
H558R were identified. It has been shown previously that sodium channels with both variants 
in “cis” position exhibit a LQTS-like dysfunction. DNA-haplotyping was performed and revealed 
that both variants reside on the same allele in case of the deceased female. Therefore, it can 
be assumed that SCN5A-A572D in association with the common variant H558R on the same 
allele might be responsible for the sudden cardiac death of the female. 
In a female patient with a clinically diagnosed LQTS and a family history of sudden cardiac 
death, the mutation KCNH2-E876X was identified. Family members were carriers of the same 
mutation and the common variant KCNH2-K897T. This common variant is associated with QTc 
interval variability and is proposed to function as a genetic modifier of LQTS disease severity. 
Family members carrying both variants exhibited only a mild QTc prolongation in resting ECG 
and experienced a syncope only once in their lifetime. However, it can only be speculated 
whether the common KCNH2 variant K897T modifies disease severity in the investigated 
family. 
 
 Introduction 
The congenital long QT syndrome (LQTS) is an inherited cardiac disease with a prevalence of 
approximately 1/2000 [1]. This disorder is characterized by prolongation of the QT interval on 
the electrocardiogram (ECG) (Fig. 26B) due to delayed ventricular repolarization (Fig. 26B); it 
is further associated with syncopes and sudden cardiac death (SCD) as a result of torsades 
des pointes (TdP) ventricular tachycardia (VT) [2].   
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Fig. 26: The cardiac electrical activity. 
(A) Prolongation of the QT interval on a surface electrocardiogram. (B) Corresponding prolongation of the action 
potential duration. Phase 0: depolarization, phase 1: fast repolarization, phase 2: plateau, phase 3: terminal 
repolarization, phase 4: resting (Modified from Amin et al. [3]). 
 
Mutations in 15 different genes coding for ion channels and their accessory subunits have 
been linked to different types of LQTS [4]. Approximately 90% of genotype-positive cases carry 
a mutation in KCNQ1 (42-54%, LQTS type 1, LQT1), KCNH2 (35-45%, LQTS type 2, LQT2) 
or SCN5A (1.7-8%, LQTS type 3, LQT3) [5–7].  
LQT2-linked loss-of-function mutations in the KCNH2-encoded hERG (Kv11.1) channel lead to 
a decrease in the rectifier K+ current (IKr) [6,8]. LQT3 associated gain-of-function mutations in 
the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel Nav1.5, may 
affect the fast inactivation of the channel resulting in a late depolarizing Na+ current (INa) [9]. 
Thus, LQT-associated mutations delay the repolarization of the ventricular action potential, 
either through a decrease of the repolarizing current (LQT2) or due to increasing the 
depolarizing current (LQT3). 
In recent years, it became evident that carriership of a mutation in the LQTS-susceptibility 
genes often fails to predict the clinical phenotype, since some carriers remain asymptomatic 
(incomplete penetrance), some only show QTc prolongation without cardiac events, whereas 
others experience serious cardiac events at an early age (variable expressivity) [10]. It is 
known that LQTS is a disorder with many non-genetic factors, amongst which age and sex 
[11,12], modifying the clinical phenotype. Furthermore, it has become clear that common 
genetic variants (with a minor allele frequency (MAF) > 5%), if associated with a mutation, 
modulate the disease severity in LQTS [3]. These common variants, which may even influence 
the QTc duration in the general population, can be located in the same or in a different gene. 
Single nucleotide polymorphisms (SNPs) in the coding regions of LQTS-related genes such 
as KCNH2 K897T [13–16] and SCN5A H558R [16] are known to influence the QT interval. In 
addition, SNPs in non-coding regions (introns, 3’UTR) of KCNQ1 are also reported to modify 
QTc duration [3,17]. 
In the current study, we present familial, clinical and genetic evidence underlining the important 
issue, that common genetic variants may modify the expressivity of LQTS in mutation carriers 
and that this mechanism may aggravate or otherwise mitigate the risk of SCD. 
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 Material and Methods 
3.3.1. Clinical characteristics and genetic analysis 
Case 1:  
A 17 years old female died suddenly and unexpected during sleep. Since no pathological 
findings were obtained by medico-legal autopsy a genetic analysis was carried out. Genomic 
DNA was extracted from blood samples using standard phenol chloroform procedures. 
Targeted mutational analysis including the major LQTS, BrS and CPVT related genes KCNQ1 
(NG_008935), KCNH2 (NG_008916), SCN5A (NG_008934), KCNE1 (NG_009091), KCNE2 
(NG_008804), KCNJ2 (NG_008798), SCN4B (NG_011710), HCN4 (NG_009063) and 20 
exons (3, 8, 14, 15, 44-47, 49, 83, 88, 90, 93, 96, 97, 100-103, 105) of RyR2 (NG008799) as 
well as the major ARVC genes PKP2 (NG_009000), DSG2 (NG_007072), DSC2 (NG_008208) 
and DSP (NG_008803) was performed using polymerase chain reaction (PCR) with published 
[18–20] and own primers (primer sequences upon request). After direct sequencing of the 
amplicons, the sequencing products were examined using a 3130xl Genetic Analyzer (Applied 
Biosystems, Germany). Analysis of the sequence data was done using the SeqScape v2.5 
software (Applied Biosystems, Germany). As this analysis revealed a potentially pathogenic 
variant, the first-degree relatives were encouraged to seek genetic counselling. After providing 
informed consent of the father and the sister of the SCD victim, blood samples were collected 
and analysed as described above. The mother died due a non-cardiac cause. 
 
Case 2: 
A 30 years old female experienced seizures and a recurrent Torsade de pointes (TdP) 
tachycardia. Under hypoxic and QT-prolonging medication a LQTS (Romano-Ward-
Syndrome) was unmasked. Genetic analysis revealed a heterozygous mutation E876X 
(c.2626G>T) in exon 12 of the KCNH2 gene. The attending physician gave the advice for an 
implantable cardioverter defibrillator (ICD). Because of the autosomal dominant inheritance of 
the LQTS and given the fact that a 58 years old aunt of the index patient had died due to SCD, 
the first-degree relatives were recommended to seek genetic counselling and undergo 
cardiological assessment including resting and exercise ECG. Standard criteria for the 
diagnosis of LQTS [21,22] were used as described. The corrected QT interval (QTc) was 
calculated using Bazett’s formula. According to the ESC guidelines [23] a clinical LQTS 
diagnosis is considered in patients with unexplained syncope and QTc ≥ 460 ms in repeated 
12-lead ECGs. After obtaining informed consent of five family members, blood samples were 
collected and exclusively exon 12 of the KCNH2 gene was analysed. The genetic analysis was 
performed as described in case 1.    
 
3.3.2. H558R and A572D haplotyping (case 1) 
The genetic analysis in case 1 revealed a double heterozygous carriership of the variants 
H558R and A572D in the SCN5A gene of the SCD victim. The common polymorphism H558R 
is known to be a modifying variant that can alter the phenotypic effects of other SCN5A 
variants. To determine if D572 existed on the same allele as H558 or R558 a polymerase chain 
reaction (PCR) of SCN5A exon 12 was performed using the forward (5’-
GCCAGTGGCACAAAAGACAGGCT-3’) and the reverse primer (5’-
GGAACTGCTGATCAGTTTGGGAGA-3’) as described by Tester et al. [24]. The amplification 
products were digested with the restriction enzyme Tsp45I (New England BioLabs, Frankfurt, 
Germany) which cleaves only the D572 allele (5’-GTSAC-3’). The digestion products were 
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separated on a 2% agarose gel; the 275 bp band was excised from the agarose gel, purified 
using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sequenced. 
 
 Results 
3.4.1. Case 1: Analysis of the SCN5A gene  
A targeted postmortem mutational analysis of the major LQTS, BrS, CPVT and ARVC related 
genes using PCR followed by direct sequencing revealed the heterozygous variant A572D 
(c.1715C>A, rs36210423) as well as the polymorphism H558R (c.1673A>G, rs1805124) in the 
SCN5A gene of the deceased female (Fig. 28A). The variant A572D has a minor allele 
frequency (MAF) of 0,37% in the European population (ExAC database) and is associated with 
a susceptibility to develop LQTS [24,25]. Both, variant and polymorphism, are localized to the 
DI-DII interdomain linker of Nav1.5 [26] (Fig. 27A); this part of the Nav1.5 channel is relatively 
non-conserved among different species (Fig. 27B).  
 
 
Fig. 27: Location of the SCN5A variants H558R and A572D. 
(A) Schematic representation of a Nav1.5 α-subunit. The polymorphism H558R and the variant A572D are located 
in the intracellular linker loop 1 of the cardiac sodium channel. DI-DIV are the four homologous domains of the α-
subunit (modified from Abriel et al. [27]). (B) Alignment of a part of the SCN5A amino acid sequence from different 
species. The position H558 is highlighted in blue and the position A572 is indicated in red. 
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Tester et al. [24] demonstrated that the SCN5A variant D572 is invariably linked to the common 
polymorphism R558 meaning both variants residing on the same allele (“cis” position). To verify 
if R558 and D572 existed on the same allele in case of the deceased female, haplotyping as 
described by Tester et al. [24] was performed (Fig. 28). The A572D heterozygote sample 
yielded gel bands of 518 bp (representing the non-cleaved A572 allele), 275 bp (representing 
the 5’-end of the cleaved D572 allele) and 243 bp (representing the 3’-end of the cleaved D572 
allele) (Fig 28B). Sequencing of the 275 bp fragment demonstrated that the variant D572 was 
in fact in “cis” position to the polymorphism R558 (Fig. 28C). 
 
 
Fig. 28: H558R and A572D haplotyping. 
(A) Sequence analysis of the SCN5A gene revealed two heterozygous nucleotide changes c.1673A>G (H558R) 
and c.1715C>A (A572D) in the SCD victim. Highlighted in orange is the SCN5A reference sequence. H = 
Histidine, R = Arginine, A = Alanine, D = Aspartic acid. (B) The two SCN5A sequence variants existed either on 
the same (option 1) or on different alleles (option 2). After PCR amplification, the products were digested with the 
restriction enzyme Tsp45I which cleaved only the D572 allele. Numbers in parentheses indicate the expected 
fragment size on an agarose gel. (C) Sequencing of the 275 bp fragment revealed that the polymorphism R558 
was on the same allele as the variant D572. 
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In case of the father and the sister of the deceased female exclusively exon 12 of the SCN5A 
gene was analysed. Both carried neither the polymorphism H558R nor the variant A572D (Fig. 
29). Hence, the sequence variants could be passed on by the mother of the SCD victim, who 
had already died due to non-cardiac causes, or arose de novo. 
 
 
Fig. 29: Family pedigree of the deceased female, case 1. 
Square symbols indicate males, round symbols females and slashed symbols mark deceased individuals. The 
arrow indicates the index patient. SCD = Sudden Cardiac Death. 
 
3.4.2. Case 2: Clinical characteristics  
The index patient (Fig. 31A, IV.1), a 30 years old female, experienced recurrent seizures and 
TdP arrhythmias. The clinical diagnosis of a LQTS was confirmed by an externally performed 
genetic analysis, which identified a heterozygous mutation E876X (c.2626G>T) in exon 12 of 
the KCNH2 gene. Further evaluation of the family history revealed that one aunt (III.4) had 
died due to sudden cardiac death at the age of 58. The mother (III.1) and two uncles (III.2 and 
III.3) of the index patient experienced a syncope once in their lifetime. The QTc was marginally 
prolonged (III.1: 450 ms, III.2: 444 ms and III.3: 436 ms). Exercise ECG testing was performed 
and showed a QTc prolongation during the recovery phase in III.2 (549 ms) and III.3 (566 ms); 
the QTc in III.1 was shortened (300 ms). The sister (IV.2) of the index patient had no syncopal 
episode so far and the QTc was 430 ms. The cousin (IV.3) reported a history of 3-4 syncopes 
at a young age, but these were rather non-vasovagal. Resting and exercise ECG showed 
normal QTc intervals, 390 ms and 420 ms, respectively. 
 
3.4.3. Case 2: KCNH2 mutation analysis 
The female index patient carried the very rare variant E876X in exon 12 of the KCNH2 gene. 
The mutation, which was first identified in a large cohort of unrelated LQTS patients [28], 
creates a stop codon through a nucleotide change from guanine to thymine at position 2626 
(GAG  TAG) in the sequence and leads to a deletion of 283 amino acids in the hERG protein 
(Fig.30). Genotyping of the mother (III.1) for the KCNH2-E876X mutation revealed a 
homozygous carriership of this mutation (Fig. 31B). However, the genetic results were not 
consistent with the cardiological findings of a moderate QTc prolongation. Therefore, a point 
mutation in the primer binding site of the wildtype allele was considered. Amplification of 
KCNH2 exon 12 with an alternative forward (5’-GGGCAAAATCACATTGGGGG-3’) and 
reverse (5’-AGGTCTGAGGCCTGGGTAAA-3’) primer identified the heterozygous state of the 
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E876X mutation (Fig. 31C). Additionally, the new primer pair detected a heterozygous 
nucleotide change (AAG  ACG) at position 2690 leading to the substitution of lysine at the 
residue 897 to threonine in the resulting protein (Fig. 31C). The polymorphism K897T is 
classified as a common variant (MAF ~24% in the European population, ExAC database) that 
is proposed as a genetic modifier in LQTS [3].  
 
 
 
Fig. 30: Topology of the hERG channel and location of the E876X mutation and the K897T polymorphism. 
Schematic topology of the hERG channel illustrating the relative positioning of channel regions and domains. The 
mutation is located at the distal C-terminus of the channel and leads to a deletion of 283 amino acids. PAS = Per-
Arnt-Sim domain, S1-S6 = Transmembrane helices, P = Pore helix, CNB = Cyclic-nucleotide-binding homology 
domain, aa = amino acids, E = Glutamic acid, X = Stop (modified from Gustina et al. [29]). 
 
3.4.4. Case 2: Segregation of the KCNH2 variants 
By family screening KCNH2-E876X and -K897T were detected in two uncles (III.2 and III.3) of 
the index patient. The sister (IV.2) and cousin (IV.3) were genotyped for the K897T 
polymorphism. Analysis of the family pedigree as well as of the sequence data indicated that 
the mutation E876X and the polymorphism K897T exist on separate KCNH2 alleles. No 
material for a genetic analysis of the deceased aunt (III.4) exist. 
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Fig. 31: Identification of the KCNH2 E876X mutation and the K897T polymorphism, case 2. 
(A) Pedigree structure of the affected family. Square symbols indicate males, round symbols females and slashed 
symbols mark deceased individuals. The Roman numerals indicate the generation number, Arabic numerals each 
individual in a given generation. The arrow indicates the index patient. SCD = Sudden Cardiac Death. (B) DNA 
analysis of the mother (III.1) with the generally used primers revealed a homozygous G  T transition at position 
2626 of KCNH2. The A  C change at nucleotide position 2690 was not detected. (C) Amplification with an 
alternative primer pair and subsequent sequence analysis identified both heterozygous nucleotide changes 
leading to the amino acid substitutions E876X and K897T in the resulting protein. E = glutamic acid, X = stop, K = 
lysine, T = threonine. 
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 Discussion 
In the present study, we describe the identification of a rare variant together with a common 
variant in a case of sudden cardiac death and in a LQTS-affected family with a history of 
sudden cardiac death. The findings provide evidence that common variants may modulate 
disease severity of LQTS and possibly enhance or weaken the risk for sudden cardiac death. 
In case of the 17-year-old female who died suddenly during sleep (case 1), two heterozygous 
variants, A572D and H558R, were identified in the SCN5A gene. Medico-legal autopsy, 
including toxicological and histological investigations, revealed no pathological findings. 
Genetic screening of the father and the sister of the deceased revealed that they were non-
carriers of both variants. The mother of the SCD victim had already died due to non-cardiac 
causes. The SCN5A variant A572D is classified as a rare variant with a MAF of 0.37% in the 
European population (ExAC database) and is furthermore associated with the susceptibility to 
develop LQTS [24,25,28]. The common SCN5A variant H558R, with a MAF of ~23% in the 
European population (ExAc database), has been shown previously to modify the phenotype of 
other SCN5A variants [30,31] and is known to influence the QT interval [16]. 
In a recent study Ortiz-Bonnin et al. [25] identified the SCN5A-A572D variant in a patient with 
an unclear cardiological phenotype and functionally characterized the variant in Xenopus 
laevis oocytes. They showed that oocytes expressing the A572D variant exhibited a significant 
gain-of-function phenotype (slower inactivation, faster recovery from inactivation) which might 
have the ability to prolong the cardiac action potential. However, based on the discordance 
between the clinical and the in vitro phenotype they classified SCN5A-A572D as a variant of 
unknown significance. Furthermore, they hypothesized that this variant may be influenced by 
other factors modifying the clinical phenotype. Tester et al. [24] performed functional studies 
of SCN5A-A572D in the context of the common SCN5A variant H558R in HEK293 cells. They 
observed that HEK293 cells expressing D572/R558-containing sodium channels (both variants 
in “cis” position) exhibited a LQT3-like dysfunction. In contrast to the study of Ortiz-Bonnin et 
al. [25] no gating kinetic or current density differences compared with wild-type channels were 
detected in cells expressing the SCN5A variant D572 alone or in the setting of H558 
(D572/H558).  
Considering these results, it can be concluded that SCN5A-A572D in association with the 
common variant H558R on the same allele could cause LQT3 and might be responsible for 
the sudden cardiac death of the 17 years old female. It cannot be ruled out that other genetic 
or non-genetic factors might have influenced disease severity. 
In the second case the index patient was a 30-year-old female with a clinically diagnosed LQTS 
and a family history of sudden cardiac death. Genetic analysis identified a heterozygous 
mutation E876X in the KCNH2 gene. Genetic screening of the family members of the index 
patient revealed heterozygous carriership of this mutation in the mother and in two uncles. 
Additionally, they were genotyped for the heterozygous KCNH2 polymorphism K897T. The 
sister and cousin of the index patient were carriers of the KCNH2-K897T polymorphism but 
not of the mutation. Evaluation of the family history revealed the sudden cardiac death of a 58-
year-old aunt of the index patient; regrettably, no medico-legal autopsy or genetic testing was 
performed.  
The KCNH2-E876X mutation was first identified in a large study cohort of LQTS patients [28] 
and leads to a C-terminal truncation of the hERG channel. Functional studies of this KCNH2 
variant are not available, but Teng et al. [32] performed a clinical and electrophysiological 
characterization of a comparable KCNH2 mutation R863X, which also causes a deletion of the 
distal C-terminus of the hERG protein. They demonstrated that KCNH2-R863X failed to form 
functional hERG channels contributing to a prolongation of the QT interval [32]. On the basis 
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of these results, the same effect could be assumed for the KCNH2 mutation E876X identified 
in the affected family. 
The common variant KCNH2-K897T (MAF ~24% in the European population, ExAc database) 
is associated with QTc interval variability in the general population [13,14,16,33–35] and is 
proposed to serve as a genetic modifier of LQTS disease severity [15,36]. However, there is 
an apparent inconsistency among the different studies. Considering genome-wide association 
studies (GWAS), in Western European [13,14,16] and North American [33] study cohorts 
KCNH2-K897T shortened the QTc interval, whereas in Finnish cohorts [34,35] the QTc interval 
was prolonged; thus, the discordant findings may be population-specific. Crotti et al. [15] 
studied a LQTS family with the KCNH2-A1116V mutation and demonstrated that disease was 
only manifested in individuals who co-inherited the minor T allele of the K897T variant on the 
non-mutant KCNH2 allele (variants in “trans” position); family members with KCNH2-A1116V 
alone were asymptomatic with a mild QTc prolongation. Controversially, Zhang et al. [36] 
showed in a LQTS family that two variants in KCNH2, the mutation A490T and the common 
variant K897T, interact with each other in “cis” orientation (minor T allele of K897T on the 
mutant KCNH2 allele). They concluded this “cis” orientation of both variants leads to a 
shortened QT interval and less severe symptoms and therefore to a reduced risk of LQTS. 
Whether the common KCNH2 variant K897T modifies disease severity in the investigated 
family can only be speculated. All three KCNH2-E876X mutation carriers with the minor T allele 
of K897T in “trans” position exhibited only a mild QTc prolongation in resting ECG and 
experienced a syncope only once in their lifetime. By contrast, the index patient carrying the 
KCNH2-E876X mutation alone experienced seizures and a recurrent Torsade de pointes (TdP) 
tachycardia; unfortunately, a QTc was not available. Therefore, it can be hypothesized that the 
minor T allele of the common variant KCNH2-K897T could play a protective role on QTc 
prolongation. However, there are some limitations for this hypothesis. The studied family was 
very small and the presence of additional QTc-modifying variants in other ion channel genes 
cannot be excluded. Furthermore, studying the functional effect of the mutation in combination 
with the common variant on the electrophysiological behaviour of the hERG channel may 
provide insights into the mechanism of QTc prolongation or shortening.  
In summary, the results underline the important issue that additional genetic modifications, like 
common genetic variants in the same gene, may influence the expressivity of LQTS in KCNH2- 
and SCN5A-mutation carriers and this could be an important aspect for risk stratification. 
Nevertheless, further studies concerning the functional consequences of 
polymorphism/mutation interactions are needed. 
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 SUMMARY 
Sudden death (SD) is defined as a natural and unexpected event in apparently healthy persons 
that occurs within the first hour after onset of symptoms. Nearly 85% of all sudden deaths are 
of cardiac origin, called sudden cardiac death (SCD). In individuals > 55 years old about 80% 
of SCD cases are a consequence of a coronary heart disease whereas in the young adult 
population (< 40 years old) SCD is often caused by a primary arrhythmia syndrome in a 
structurally normal heart. Among these syndromes are the two main ion channel diseases: 
long QT syndrome (LQTS) and Brugada syndrome (BrS). Since these diseases are of genetic 
origin, relatives of SCD victims or clinically affected patients may be at risk, despite being 
asymptomatic. Furthermore, within affected families variable expressivity and incomplete 
penetrance of the clinical phenotype are frequent.  
The present thesis describes the identification and characterization of sequence variants in the 
cardiac ion channel genes KCNH2 and SCN5A. The variants were found in sudden cardiac 
death victims, in patients with ion channel diseases and in their family members. The results 
support the growing awareness that carriership of a single mutation often fails to predict the 
clinical phenotype and that additional genetic modifications may influence the clinical 
manifestation of the disease. 
Sequence variants in the KCNH2 gene, which encodes the α-subunit of the voltage-gated 
potassium channel hERG, may cause a prolonged repolarization of the cardiac action potential 
(prolonged QT interval on the ECG) either through disruption of channel gating or reduction of 
intracellular trafficking to the plasma membrane.  
In a LQTS patient the mutation L69P in the PAS domain of the hERG channel was identified. 
Electrophysiological studies in HEK293 cells expressing the hERG-L69P mutant channel 
unveiled a reduced channel function compared to cells expressing the WT channel. 
Additionally, the cellular distribution of EGFP-tagged hERG-WT and hERG-L69P mutant 
channels in HEK293 cells was monitored by CLSM. The GFP fluorescence in hERG-L69P 
expressing cells was stronger in intracellular compartments than in the plasma membrane. 
Furthermore, a comparative quantification of isolated plasma membrane patches showed that 
the relative fluorescence intensity of the hERG-L69P mutant was about 50% reduced 
compared to that of hERG-WT. These results indicate that the mutation L69P causes both 
functional and trafficking defects of the hERG channel. Incubation of hERG-L69P mutant 
expressing HEK293 cells at 27°C, which should promote protein folding, did not improve 
channel trafficking. Three additional channel variants (L69A, L69D and L69G) exhibited larger 
currents than the hERG-L69P mutant but with different deactivation kinetics compared to the 
WT channel. In summary, these data suggest that an amino acid exchange at position 69 in 
the PAS domain of the hERG protein has a negative effect on channel kinetics as well as on 
channel trafficking, which supports the clinical diagnosis of a LQTS. 
In a female patient with a clinically diagnosed LQTS the mutation KCNH2-E876X was 
identified. The index patient experienced seizures and a recurrent Torsade de pointes (TdP) 
tachycardia. Three family members carried the common variant KCNH2-K897T in addition to 
the KCNH2-E876X mutation; they exhibited only a mild QTc prolongation in resting ECG and 
experienced a syncope only once in their lifetime. The effect of KCNH2-K897T on the QTc 
interval is controversially discussed. Additionally, this variant is proposed to function as a 
genetic modifier of LQTS disease severity. In case of the studied family it can be hypothesized 
that the common KCNH2 variant K897T modulates disease severity, but this remains to be 
elucidated.  
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The SCN5A gene encodes the α-subunit of the cardiac sodium channel Nav1.5. Mutations in 
the SCN5A gene cause a change in the cardiac action potential either through an increase 
(gain-of-function mutations, LQTS) or a decrease of the depolarizing sodium current (loss-of-
function mutations, BrS). 
In a case of SCD of a 16-year-old female genetic analysis identified a heterozygous SCN5A 
variant E1053K, which was previously associated with BrS as well as with LQTS. Genetic 
screening of the family members revealed a heterozygous carriership of the variant in her 
mother and in her cousin of second degree; the aunt of the deceased was a homozygous 
carrier of the SCN5A-E1053K variant. Surprisingly, neither a heterozygous nor the 
homozygous carrier of the variant exhibited any pathological cardiac phenotype assuming 
additional genetic factors in the SCN5A gene of the SCD victim. MLPA analysis identified a 
heterozygous deletion in the promotor region of SCN5A of the deceased but not in other family 
members. To further localize the deletion in the 5’ upstream region of the SCN5A gene, a RT-
qPCR was performed, which confirmed the deletion in a region extending from position -1845 
to -1610 upstream of the major transcription initiation site. It is hypothesized that variants in 
the promoter region may affect transcriptional activity of the SCN5A gene and thereby 
modulate the susceptibility to arrhythmia syndromes. In conclusion, the results suggest that 
SCN5A-E1053K is not an independent pathogenic variant but in association with additional 
genetic modifications might contribute to an increased risk for SCD. 
In a second SCD case two heterozygous variants, A572D and H558R, were identified in the 
SCN5A gene of a 17 years old female. SCN5A-A572D was previously associated with a 
susceptibility to develop LQTS but rather in combination with other genetic modifications. In a 
previous study, it was shown SCN5A-A572D in association with the common variant H558R 
on the same allele (“cis” position) cause a LQTS-like dysfunction in HEK293 cells. To verify if 
both variants were located on the same allele in case of the deceased female, DNA haplotyping 
was performed. This analysis revealed that A572D and H558R were in fact in “cis” position on 
the SCN5A gene. It can be concluded that D572 in the setting of R558 on the same allele 
might be responsible for the sudden cardiac death of the young female.  
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 ZUSAMMENFASSUNG 
Der plötzliche Tod ist definiert als ein natürliches und unerwartetes Ereignis bei zuvor gesund 
erscheinenden Personen, welches innerhalb der ersten Stunde nach Beginn der Symptome 
auftritt. Fast 85% aller plötzlichen Todesfälle sind kardialen Ursprungs; daher wird vom 
plötzlichen Herztod gesprochen („sudden cardiac death“, SCD). Bei älteren Personen (> 55 
Jahre) sind etwa 80% der SCD-Fälle eine Folge einer koronaren Herzerkrankung, während 
bei jüngeren Menschen (<40 Jahre) häufig ein primäres Arrhythmiesyndrom bei strukturell 
unauffälligem Herzen vorliegt. Zu diesen Arrhythmiesyndromen gehören die beiden 
wichtigsten Ionenkanalerkrankungen: das Long QT-Syndrom (LQTS) und das Brugada-
Syndrom (BrS). Da diese Erkrankungen häufig eine genetische Ursache haben, können 
Angehörige von SCD-Opfern oder von klinisch auffälligen Personen, obwohl sie 
asymptomatisch sind, gefährdet sein. Darüber hinaus beobachtet man innerhalb der 
betroffenen Familien häufig eine unvollständige Penetranz und eine variable Expressivität des 
klinischen Phänotyps. 
Die vorliegende Arbeit beschreibt die Identifizierung und Charakterisierung von 
Sequenzvarianten in den kardialen Ionenkanalgenen KCNH2 und SCN5A. Die Identifizierung 
von Sequenzvarianten erfolgte bei am plötzlichen Herztod verstorbenen Personen, bei 
Patienten mit Ionenkanalerkrankungen und deren Familienangehörigen. Die Ergebnisse legen 
nahe, dass eine genetische Variante nicht immer einen klinischen Phänotyp hervorrufen muss 
und zusätzlich genetische Modifikationen vorliegen können, welche die klinische Ausprägung 
einer Erkrankung beeinflussen. 
Sequenzvarianten im KCNH2 Gen, das für die α-Untereinheit des spannungsabhängigen 
Kaliumkanals hERG kodiert, können zu einer Verlängerung des kardialen Aktionspotentials 
(verlängertes QT-Intervall im EKG) führen; der Grund hierfür kann entweder in einer 
funktionellen Störung des Kanals liegen oder die Folge eines verminderten intrazellulären 
Transports des Kanals zur Plasmamembran sein. 
In einem LQTS-Patienten wurde in der PAS-Domäne des hERG Kanals die Mutation L69P 
detektiert. Elektrophysiologische Studien an HEK293 Zellen zeigten, dass Zellen, welche die 
hERG-L69P Mutante exprimierten, im Vergleich zu Zellen, die den hERG-WT exprimierten, 
eine reduzierte Kanalleitfähigkeit besitzen. Zusätzlich wurde mittels CLSM die zelluläre 
Verteilung von GFP-markierten hERG-WT und hERG-L69P Kanälen in HEK293 Zellen 
untersucht. Bei der hERG-L69P Mutante war die Fluoreszenzintensität in den intrazellulären 
Kompartimenten stärker als in der Plasmamembran. Darüber hinaus wurde die 
Fluoreszenzintensität von isolierten Plasmamembran-Fragmenten quantifiziert und verglichen; 
dies zeigte, dass die Fluoreszenzintensität der hERG-L69P Mutante im Vergleich zum hERG-
WT um etwa 50% reduziert war. Diese Ergebnisse deuten darauf hin, dass die L69P Mutation 
sowohl eine funktionelle Störung des hERG Kanals verursacht, als auch dessen Transport zur 
Plasmamembran beeinflusst. Die Verwendung einer erniedrigten Inkubationstemperatur von 
27°C, was die Proteinfaltung begünstigen sollte, führte nicht zu einem gesteigerten Transport 
des hERG-L69P Kanals zur Plasmamembran. Bei den zusätzlichen hERG Varianten (L69A, 
L69D und L69G) konnten im Vergleich zur hERG-L69P Mutante größere Ströme gemessen 
werden, allerdings mit einer veränderten Deaktivierungskinetik verglichen mit dem hERG-WT. 
Zusammenfassend lässt sich feststellen, dass ein Aminosäureaustausch an Position 69 in der 
PAS-Domäne des hERG Proteins sowohl die Kinetik als auch den Transport des hERG Kanals 
beeinflusst, was sich mit der klinischen Diagnose eines LQTS vereinbaren lässt. 
Bei einer Patientin mit einem klinisch diagnostizierten LQTS wurde im KCNH2 Gen die 
Mutation E876X identifiziert. Die Indexpatientin litt unter Krampfanfällen und einer 
wiederkehrenden Torsade de pointes (TdP) Tachykardie. Bei drei Familienangehörigen wurde 
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zusätzlich zur Mutation die häufige KCNH2 Variante K897T detektiert; die QTc-Zeit im Ruhe-
EKG war nur grenzwertig verlängert und bei allen kam es nur einmal im Leben zu einer 
Synkope. Der Einfluss der Variante KCNH2-K897T auf das QTc-Intervall wird kontrovers 
diskutiert. Es wird zudem vermutet, dass diese häufige genetische Variante die Schwere einer 
LQTS-Erkrankung modifiziert. Dieser Mechanismus wird auch im Falle der untersuchten 
Familie angenommen, dies bedarf aber noch weiterer Abklärung. 
Das SCN5A Gen codiert für die α-Untereinheit des kardialen Natriumkanals Nav1.5. 
Mutationen im SCN5A Gen führen entweder zu einer Zunahme (Funktionsgewinn-Mutation, 
LQTS) oder zu einer Abnahme (Funktionsverlust-Mutation, BrS) des depolarisierenden 
Natriumstromes und bewirken dadurch eine Veränderung des kardialen Aktionspotentials.  
Im Fall des plötzlichen Herztodes eines 16-jährigen Mädchens wurde im SCN5A Gen die 
heterozygote Variante E1053K detektiert, die zuvor schon mit dem BrS als auch mit dem LQTS 
assoziiert war. Eine genetische Untersuchung der Familienangehörigen zeigte, dass die 
Mutter der Verstorbenen und ein Cousin zweiten Grades heterozygote Träger der Variante 
sind; bei einer Tante der Verstorbenen konnte die SCN5A Variante E1053K in homozygoter 
Form nachgewiesen werden. Überraschenderweise zeigten weder ein heterozygoter Träger 
noch die homozygote Trägerin der Variante bei einer kardiologischen Untersuchung einen 
pathologischen Phänotyp; es wurde daher vermutet, dass bei der Verstorbenen zusätzliche 
genetische Modifikationen vorliegen. Mittels einer MLPA-Analyse wurde eine heterozygote 
Deletion im Promotorbereich des SCN5A Gens der Verstorbenen identifiziert, welche jedoch 
nicht in anderen Familienangehörigen nachgewiesen werden konnte. Um die Deletion in der 
5‘-Richtung gelegenen Region des SCN5A Gens zu bestätigen und näher eingrenzen zu 
können, wurde ein RT-qPCR durchgeführt. Die Deletion konnte bestätigt werden und liegt 
zwischen Position -1845 bis -1610 vor der Transkriptionsstartstelle. Es wird vermutet, dass 
Sequenzvarianten im Promotorbereich des SCN5A Gens die Transkriptionsaktivität desselben 
beeinflussen und dadurch das Arrhythmierisiko erhöhen. Im vorliegenden Fall deuten die 
Ergebnisse darauf hin, dass SCN5A-E1053K keine unabhängige pathogene Variante ist, 
sondern in Verbindung mit zusätzlichen genetischen Modifikationen das Risiko eines 
plötzlichen Herztodes erhöht. 
In einem zweiten SCD Fall eines 17-jährigen Mädchens, wurden, ebenfalls im SCN5A Gen, 
zwei heterozygote Sequenzvarianten, A572D und H558R, identifiziert. Es wird vermutet, dass 
SCN5A-A572D in Kombination mit anderen genetischen Modifikationen das Risiko ein LQTS 
zu entwickeln erhöht. In einer früheren Studie konnte gezeigt werden, dass SCN5A-A572D in 
Verbindung mit der häufigen Variante H558R auf dem gleichen Allel („cis“-Position) in 
HEK293-Zellen eine LQTS-ähnliche Dysfunktion verursacht. Um zu testen, ob im vorliegenden 
Fall ebenfalls beide Varianten auf demselben Allel vorlagen, wurde eine DNA-Haplotypisierung 
durchgeführt. Diese Analyse bestätigte die „cis“-Position der beiden Varianten A572D und 
H558R auf dem SCN5A Gen. Es kann angenommen werden, dass D572 in Verbindung mit 
R558 auf dem gleichen Allel des SCN5A Gens bei dem plötzlichen Herztod der jungen Frau 
ursächlich gewesen sein könnte. 
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